INDEX TO VOLUME 179

Author Index

Aaltonen, L.-M., 682
Aarbiou, J., 1108
Aavitsland, P., 223
Abath, F. G. C., 1502
Abbal, M., 1309
Abbruscato, F., 1206
Abrams, E. J., 52
Abu-Elyazeed, R., 107, 382
Acheson, D. W. K., 503
Adams, O., 1046
Adler, G., 398
Aichelburg, A., 209
AIDS Clinical Trials Group 347 Study Team, 808
Aikawa, M., 283
Ajizian, S. J., 939
Akaibe, D., S155
Akamituna, P., S8
Akridge, R. E., 548
Alam, K., 390
Albers, G. M., 1190
Albert, J. M., 849
Alcorn, T. M., 371
Aldrich, W., 245
Alexander, J. P., 25
Alexander, J. P., Jr., 230
Al-Homsi, A. S., 240
Aligui, G., 996
Allen, R. C., 151
Allsopp, C. E. M., 287
Alric, L., 1309
Al-Shboul, Q., 329
Al-Tawfiq, J. A., 1283
Alter, H. J., 1055
Amblard, J. P., S65
Ambrosino, D. M., 513
Amiel, C., 83
Ammon, A., 1274
Amoudy, H. A., 637
Andersen, J., S408
Andersen, P., 637
Anderson, J. L., 1094
Anderson, L. J., 25
Anderson, R. M., 883
Ando, T., 1334
Andreasson, A., 172
Andrews, J., 1352
Angarano, G., 1534
Anguita, J., 734
Angus, C. W., 192
Ansari, A. A., S188
Antinori, A., 1025
Anton, K. E., 92
Aplasca, M.-R., 729
Arancia, S., 201
Ardito, F., 1025
Ariel Core Investigators, 319
Aronson, N., 337
Artenstein, A. W., 59, 1310
Aryeetey, M. E., 1515
Asbury, A. K., 1183
Ashkenazi, S., 1565
Ashley, R., 311
Assad-Antunes, F., 1259
Astemborski, J., 1004, 1297
Aukrust, P., 74
Austin, D. J., 883
Austrian, R., S338
Auvinen, E., 682
Awadzi, K., 738
Azen, S. P., 697
Aziz, N., 843
Baba, T. W., S408
Badaro, R., 1226
Bagby, G. J., 1441
Baglin, A. C., 497
Bahr, G. M., 83
Baier, K., 209
Baize, S., S65
Baker, C. J., 142, 576, 1410
Balzarini, J., 709
Bamji, M., 52
Banerjee, S. N., 442
Bangkok Collaborative Perinatal HIV Transmission Study Group, 590
Banks, S. M., 136
Barakamfitiye, D., S283
Barbier, C. S., 954
Bardeguez, A., 319
Barin, F., 68
Barker, E., S485
Barnes, P. F., 1213
Barnett, B. J., 442
Barraza, E. M., 1531
Barré-Sinoussi, F., 44
Barth, J., S148
Barthe, C., 37
Barthold, S. W., 734
Baseler, M., 849
Bassily, S., 107
Baughman, W., 449
Baughn, R. E., 1206
Beall, B., 627
Beasley, R. P., 1319
Becker, M., 1375
Bedini, J. L., 475
Begg, N., 1569
Bélanger, G., 1254
Bele, O., S283
Bellamy, R., 721
Bennion, D. W., 1094
Benoni, D. D., S65
Benson, D. R., 1226
Berendt, A. R., 291
Berg, G., 398
Bergamini, A., 832
Bergé, F., 1
Berger, C., 240
Bergeron, M. G., 1101, 1162
Bergmeier, L., S489
Bergqvist, Y., 974
Bermudez, S., 1388
Bernacky, B. J., S408
Bernard, N. F., 538
Berney, M., 1326
Bernstein, D. I., 303
Berry, J. D., 180
Bertherat, E. J., S65
Bertolli, J., S28, S98, S170
Bessen, D. E., 627
Bessou, G., 151
Best, J. M., 234
Bethel, J., 567
Bevin, A. A., 751
Beyrer, C., 59
Bhadrakom, C., 590
Bhatt, S. M., 264
Bienzle, U., 1042
Binley, J. M., 527
Birkenmeyer, L. G., 1242
Birx, D. L., 59, 337, 817
Bishai, W. R., 1297
Bix, M., S305
Björkman, A., 974, 989
Blackbourn, D. J., 237
Blanchard, T. G., 725
Blaser, M. J., 1523
Blétry, O., 497
Bloemena, E., 1108
Bloom, A. S., S92
Bloomfield, G., 217
Boakye, D., 1577
Bobak, D. A., S331
Bode, G., 398, 690
Boesch, C., S54, S120
Bofill, M., 352
Boivin, G., 1101
Bolacchi, F., 832
Bolan, G., 729
Bomsel, M., S448
Bone-Mane, G., 1
Bonnefoy, J.-Y., 1326
Bonnet, M.-J., S1, S8
Bonneville, M., 1
Bopp, C., 1416
Bornstein, S. R., 1048
Borrow, R., 1569
Borthwick, N. J., 352
Boshoff, C., 234
Bostic, J. R., 619
Boswell, S. L., 345
Boswell, T., 1312
Bothamley, G. H., 1051
Bourgeois, A. L., 382
Bowden, R., 311
Boyer, P. J., 1388
Boyle, M. D. P., 907
Braconier, J.H., 172
Bradney, A. P., 1264
Brandt, M. E., 449
Brar, S. S., S188
Brassard, N., 37
Bray, M., S224, S240, S248
Breiman, R. F., 414
Breman, J. G., S139
Brenner, H., 398, 690
Bresler, H. S., 245
Bressler, D. S., S28, S108, S170, S177
Breuil, J., 1173
Breukels, M. A., 1152
Briles, D. E., 414
Brink, A., 1108
Brinkman, J., 1502
Brisabois, A., 1173
Brittenham, G. M., 283
Broström, C., 1542
Brouwer, M., 825
Brown, C. R., 1573
Brown, D., 16
Brown, F. M., 107
Brown, K. E., 619
Brück, W., 1557
Brundage, J. F., 1531
Brunham, R. C., 180
Bryan, R., 1449
Bryant, A. E., 1293
Bryant, M., 1132
Bryla, D. A., 1565
Bryson, Y., 1395
Bryson, Y. J., 1388
Buates, S., 1485
Buchbinder, S. P., 717, 1264
Buffington, J., S92
Buhles, W., 1352
Bulkow, L., 101
Burkard, R. F., 264
Burns, J. L., 1190
Burt, F. J., S98, S177
Burton, D. R., S235
Bush, T. J., 871
Busico, K. M., S102
Bustos, D. G., 1587
Bwaka, M. A., S1, S11, S13, S36, S98, S268, S274
Bwayo, J., S401
Cai, S., 1086
Calabrò, M. L., 1534, 1591
Calain, P., S1, S36, S268, S274
Calaor, A. B., S115
Calderon, C., 1553
Caliendo, A. M., 808
Cama, R. I., 1139

INDEX TO VOLUME 179

Author Index

Aaltonen, L.-M., 682
Aarbiou, J., 1108
Aavitsland, P., 223
Abath, F. G. C., 1502
Abbal, M., 1309
Abbruscato, F., 1206
Abrams, E. J., 52
Abu-Elyazeed, R., 107, 382
Acheson, D. W. K., 503
Adams, O., 1046
Adler, G., 398
Aichelburg, A., 209
AIDS Clinical Trials Group 347 Study Team, 808
Aikawa, M., 283
Ajizian, S. J., 939
Akaibe, D., S155
Akamituna, P., S8
Akridge, R. E., 548
Alam, K., 390
Albers, G. M., 1190
Albert, J. M., 849
Alcorn, T. M., 371
Aldrich, W., 245
Alexander, J. P., 25
Alexander, J. P., Jr., 230
Al-Homsi, A. S., 240
Aligui, G., 996
Allen, R. C., 151
Allsopp, C. E. M., 287
Alric, L., 1309
Al-Shboul, Q., 329
Al-Tawfiq, J. A., 1283
Alter, H. J., 1055
Amblard, J. P., S65
Ambrosino, D. M., 513
Amiel, C., 83
Ammon, A., 1274
Amoudy, H. A., 637
Andersen, J., S408
Andersen, P., 637
Anderson, J. L., 1094
Anderson, L. J., 25
Anderson, R. M., 883
Ando, T., 1334
Andreasson, A., 172
Andrews, J., 1352
Angarano, G., 1534
Anguita, J., 734
Angus, C. W., 192
Ansari, A. A., S188
Antinori, A., 1025
Anton, K. E., 92
Aplasca, M.-R., 729
Arancia, S., 201
Ardito, F., 1025
Ariel Core Investigators, 319
Aronson, N., 337
Artenstein, A. W., 59, 1310
Aryeetey, M. E., 1515
Asbury, A. K., 1183
Ashkenazi, S., 1565
Ashley, R., 311
Assad-Antunes, F., 1259
Astemborski, J., 1004, 1297
Aukrust, P., 74
Austin, D. J., 883
Austrian, R., S338
Auvinen, E., 682
Awadzi, K., 738
Azen, S. P., 697
Aziz, N., 843
Baba, T. W., S408
Badaro, R., 1226
Bagby, G. J., 1441
Baglin, A. C., 497
Bahr, G. M., 83
Baier, K., 209
Baize, S., S65
Baker, C. J., 142, 576, 1410
Balzarini, J., 709
Bamji, M., 52
Banerjee, S. N., 442
Bangkok Collaborative Perinatal HIV Transmission Study Group, 590
Banks, S. M., 136
Barakamfitiye, D., S283
Barbier, C. S., 954
Bardeguez, A., 319
Barin, F., 68
Barker, E., S485
Barnes, P. F., 1213
Barnett, B. J., 442
Barraza, E. M., 1531
Barré-Sinoussi, F., 44
Barth, J., S148
Barthe, C., 37
Barthold, S. W., 734
Baseler, M., 849
Bassily, S., 107
Baughman, W., 449
Baughn, R. E., 1206
Beall, B., 627
Beasley, R. P., 1319
Becker, M., 1375
Bedini, J. L., 475
Begg, N., 1569
Bélanger, G., 1254
Bele, O., S283
Bellamy, R., 721
Bennion, D. W., 1094
Benoni, D. D., S65
Benson, D. R., 1226
Berendt, A. R., 291
Berg, G., 398
Bergamini, A., 832
Bergé, F., 1
Berger, C., 240
Bergeron, M. G., 1101, 1162
Bergmeier, L., S489
Bergqvist, Y., 974
Bermudez, S., 1388
Bernacky, B. J., S408
Bernard, N. F., 538
Berney, M., 1326
Bernstein, D. I., 303
Berry, J. D., 180
Bertherat, E. J., S65
Bertolli, J., S28, S98, S170
Bessen, D. E., 627
Bessou, G., 151
Best, J. M., 234
Bethel, J., 567
Bevin, A. A., 751
Beyrer, C., 59
Bhadrakom, C., 590
Bhatt, S. M., 264
Bienzle, U., 1042
Binley, J. M., 527
Birkenmeyer, L. G., 1242
Birx, D. L., 59, 337, 817
Bishai, W. R., 1297
Bix, M., S305
Björkman, A., 974, 989
Blackbourn, D. J., 237
Blanchard, T. G., 725
Blaser, M. J., 1523
Blétry, O., 497
Bloemena, E., 1108
Bloom, A. S., S92
Bloomfield, G., 217
Boakye, D., 1577
Bobak, D. A., S331
Bode, G., 398, 690
Boesch, C., S54, S120
Bofill, M., 352
Boivin, G., 1101
Bolacchi, F., 832
Bolan, G., 729
Bomsel, M., S448
Bone-Mane, G., 1
Bonnefoy, J.-Y., 1326
Bonnet, M.-J., S1, S8
Bonneville, M., 1
Bopp, C., 1416
Bornstein, S. R., 1048
Borrow, R., 1569
Borthwick, N. J., 352
Boshoff, C., 234
Bostic, J. R., 619
Boswell, S. L., 345
Boswell, T., 1312
Bothamley, G. H., 1051
Bourgeois, A. L., 382
Bowden, R., 311
Boyer, P. J., 1388
Boyle, M. D. P., 907
Braconier, J.H., 172
Bradney, A. P., 1264
Brandt, M. E., 449
Brar, S. S., S188
Brassard, N., 37
Bray, M., S224, S240, S248
Breiman, R. F., 414
Breman, J. G., S139
Brenner, H., 398, 690
Bresler, H. S., 245
Bressler, D. S., S28, S108, S170, S177
Breuil, J., 1173
Breukels, M. A., 1152
Briles, D. E., 414
Brink, A., 1108
Brinkman, J., 1502
Brisabois, A., 1173
Brittenham, G. M., 283
Broström, C., 1542
Brouwer, M., 825
Brown, C. R., 1573
Brown, D., 16
Brown, F. M., 107
Brown, K. E., 619
Brück, W., 1557
Brundage, J. F., 1531
Brunham, R. C., 180
Bryan, R., 1449
Bryant, A. E., 1293
Bryant, M., 1132
Bryla, D. A., 1565
Bryson, Y., 1395
Bryson, Y. J., 1388
Buates, S., 1485
Buchbinder, S. P., 717, 1264
Buffington, J., S92
Buhles, W., 1352
Bulkow, L., 101
Burkard, R. F., 264
Burns, J. L., 1190
Burt, F. J., S98, S177
Burton, D. R., S235
Bush, T. J., 871
Busico, K. M., S102
Bustos, D. G., 1587
Bwaka, M. A., S1, S11, S13, S36, S98, S268, S274
Bwayo, J., S401
Cai, S., 1086
Calabrò, M. L., 1534, 1591
Calain, P., S1, S36, S268, S274
Calaor, A. B., S115
Calderon, C., 1553
Caliendo, A. M., 808
Cama, R. I., 1139

Cammarata, C., 1423
Campbell, D., 1495
Campbell, G. L., 230
Campbell, J. R., 382
Canete-Miguel, E., 1587
Canfield, C. J., 1587
Cannon, J. G., S375
Cao, Y., 527
Capozzi, M., 832
Cappannoli, L., 832
Cappello, M., 1235
Capron, A., 83
Caringal, R. M., 627
Carlone, G. M., 1433
Carlquist, J. F., 1094
Carpenter, J., 1416
Carrington, M., 1004
Carroll, A. R., 291
Carter, R. F., 1305
Cartwright, K., 1569
Casademont, J., 475
Casado, J. L., 1553
Casin, I., 1173
Cassone, A., 201
Caterino-de-Araujo, A., 1591
Catucci, M., 361
Cave, M. D., 1213
Cebrián, M., 475
Cecilia, D., 1365
Cendoroglo, M., 503
Cernescu, C., 230
Chadderdon, R. C., 1235
Chadee, K., 1495
Chaisson, R. E., 1297
Chaitt, D. G., 849
Chalmers, M. L., 1242
Chambers, H. F., S353
Chang, T.-T., 275
Changalucha, J., 16
Chaouat, G., 44
Chaudhri, G., 217
Chaudhry, M. R., 527
Chearskul, S., 590
Chen, C.-Y., 1283
Chen, D.-S., 367
Chepurnov, A. A., S218
Cherel, Y., S54
Cherrington, J. M., 92
Chesney, M., 1375
Chhatwal, G. S., 901
Chiang Mai HEPS Working Group, 59, 1049
Chieco-Bianchi, L., 1534, 1591
Chikkala, N. F., S188
Childs, J. E., S155, 1469
Chinayon, P., 590
Cho, C. J., 1345
Chohan, B., S401
Chong-Jin, O., 259
Chotpitayasunondh, T., 590
Christiansen, C., 434
Chrousos, G. P., 1048
Churilla, A. M., 382
Cicconi, R., 832
Cieri, R., 513
Cingolani, A., 1025
Cinta Cid, M., 475
Clancy, K. A., 871
Clark, R. A., S309
Clark, S., 1569
Clarke, M. J., 1469
Clemens, J. D., 107, 382
Clements, H., 1312
Clutterbuck, D., 686
Cobbs, C. G., S360
Cohen, A., 403
Cohen, I. R., 403
Cohen, M. S., 371, S375
Coiana, A., 1007
Colebunders, R., S1, S8, S11, S13, S18, S259, S268
Coleman, R., S148
Colfax, G., 717
Colizzi, G. M. V., 832
Collatz, E., 1173
Collier, A., 548
Collier, A. C., 249
Collignon, P., 1592
Collman, R. G., S422
Commission de Lutte contre les Epidémies à Kikwit, S28, S36, S76, S87
Compton, S. J., 677
Comstock, G. W., 1297
Cone, R. W., 311
Conley, L. J., 871
Conn, L. A., 449
Connick, E., 799
Connolly, B. M., S203
Conry-Cantilena, C., 1055
Converse, P. J., 1297
Cook, N., S489
Cookson, S. T., 751
Coombs, R. W., 249
Cooney, E. L., 493
Cooper, D. A., 1549
Cooper, P. J., 738
Corachán, M., 475
Córdova, M., 1326
Corey, G. R., 1157
Corey, L., 311, 548, 1077
Corrah, T., 721
Cottingham, M., S108
Coutinho, E. M., 1502
Coutinho, R. A., 825
Crain, M. J., 414
Cranage, M., S489
Crawford, J. M., 1264
Cromeans, T. L., 37
Cropp, C. B., 522
Cryptococcal Active Surveillance Group, 449
Cryz, S. J., 522
Cullinan, T., 1580
Currier, J. S., 808
Cutler, J. E., 1477
Cu-Uvin, S., S493
Czinn, S. J., 725
Daenke, S., 291
Dagan, R., 1565
Daibata, M., 1046
Dale, D. C., S342, 1038, 1301
D'Ambrosio, J. A., 303
Danner, S., 254
Danner, S. A., 790
D'Aquila, R. T., 345, 808
Darcissac, E., 83
Davey, R. T., Jr., 849
Davidson, F., 1070
Davies, M. L., 612
Davis, C., 337
Davis, I. C., 600
Davis, K. J., S203, S248
Davis, R. H., 371
Day, R. D., 329
Dayrit, M. M., S115
De Roo, A., S1, S11, S13, S98, S170, S268
Dean, R. T., 217
De Bernardis, F., 201
de Bruijn, I. A., 31
Déchanet, J., 1
Deeks, S. G., 1375
de Goede, R. E. Y., 254
DeGruttola, V., 808
Dekkers, P. E. P., 646
Deloron, P., 980
de los Santos-Fortuna, E., 1591
De Luca, A., 1025
DeMarcus, T. A., S108, S281
Demeter, L. M., 1405
De Milito, A., 361
Demin, F., 832
Demissie, A., 637
Dennis, D. T., 931
Dennis, M., S489
De Paoli, P., 1016
de Ruiter, A., 234
Desai, S. M., 1242
Descamps-Latscha, B., 151
Deschênes, M., 1254
De Serres, G., 37
Detels, R., 843, 859
Dewar, R., 849
de Wolf, F., 790
Dewulf, J., 83
Dezube, B. J., 843
Dgedge, M., 475
Dhillon, A. P., 775
Dickover, R., 1388
Dietze, R., 1259
Dillner, J., 1016
Dillon, M., 1388
DiMango, E., 1449
Dinarello, C. A., S294, 1313
Dinauer, M. C., 217
Dind, F., S120
Dionne, M., 37
Dippmann, A. K., 1042
Do, A. N., 442
Dodson, J. M., 460
Dohm, D., S148
Domingues, A. L. C., 1502
Domingues, L. A. W., 1502
Donati, F., S120
Dowell, S. F., S87
Doyle, C., S489
Drew, W. L., 1352
Duffaut, M., 1309
Dunkler, A., 709
Dunn, B., 240
Duque, U. H., 1259
Durbin, A. P., 1345
Dusek, A., 1116
Easley, K., 1395
Edelman, L., 1094
Eeftinck Schattenkerk, J. K. M., 254
Efron, B., 249, 1356
Eguale, T., 637
Eidman, K., S475
Elkins, W. R., 1345
Ellerbrock, T. V., 871
Ellner, J. J., 945
El-Masry, N. A., 107
El Mohamady, H., 107
Emerman, M., 548
English, B. K., 939
Englund, J. A., 576
Ennis, F. A., 295, 755
Erb, P., 705
Erker, J. C., 1242
Ernst, R. K., S326
Eron, J. J., 808, 1259
Espevik, T., 74
Essex, M. E., 68
Eubanks, A. C., 460
Eulderink, F., 1459
European Network for In Utero Transmission of HIV-1, 44
Evans, T. G., 1124
Evans-Strickfaden, T., 871
Eyssen, X., 790
Eyster, M. E., 1062
Facklam, R. R., 414
Fadda, G., 1025
Faggioli, E., 832
Fahey, J. L., 843
Fairbanks, L. D., 352
Fallon, R. E., 612
Falloon, J., 849
Falsey, A. R., 1268
Fan, Z., 329
Fankhauser, R. L., 1334
Farci, P., 1007
Farley, J., 52
Färnert, A., 989
Farzan, N., 1565
Favero, A., 1534
Feldman, H., S28, S98, S102
Feldman, M., 1449
Ferebee, T. L., S36, 1469
Fernandez, B., S54
Ferrante, A., 1305
Ferrieri, P., 1030

Fey, P. D., 1561
Figueroa, D., 1139
Fikrig, E., 734
Filella, X., 475
Finley, R., 1197
Fiore, J. R., 1534
Fiorentino, T. R., 627
Fischer, W., 371
Fiscus, S., 576
Fiscus, S. A., 1259
Fitzgerald, M. A., 101
Fitzgerald, T., 1124
Flaitz, C. M., 763
Flancbaum, L. J., 245
Flanigan, T. P., 1310, S493
Fleerackers, Y., S76, S98, S102, S268
Flock, B., 714
Formenty, P., S48, S54, S120
Fort, M., 1309
Fortuin, D., 790
Fowell, D. J., S305
Fowler, V. G., 1157
Fox, A., 1569
Fox, L., 799
Franco, M. A., S466
Frank, I., 808
Frankel, S., 527
Freedman, L. R., S291
Freeman, W. R., 697, 1249
French, E. L., 907
Fridkin, M., 403
Frodsham, A., 187
Frøland, S. S., 74
Frosch, M., 115
Frutos, B., 1553
Fu, S., 217
Fujihashi, K., S480
Fulhorst, C. F., S115
Fultz, P. N., 600, S418, S470
Fyfe, G., 849
Gachihi, G., 996
Gaines, H., 1549
Galgiani, J. N., 518
Galil, K., 101
Gandia, J., 567
Garber, R. L., 1190
Garcia, F., 475
Garner, R. P., 337
Gary, H. E., Jr., 230
Gasanova, L., 1416
Gaucher, D., 1495
Gaviria, J. M., 1038, 1301
Gaydos, J. C., 1531
Geisbert, J. B., S148, S224
Geisbert, T. W., S108, S203, S224, S248
Geitz, C., 115
Gek Keow, L., 259
Gentsch, J. R., 1139
Georges, A.-J., S65
Georges-Courbot, M.-C., S65
Gerber, J., 1557
Gerber, J. G., 808
Gessani, S., 832
Gesty-Palmer, D., 1157
Getty, M., 101
Ghassemi, M., 924
Ghiasi, H., 1086
Gibble, J. W., 1055
Gibbons, D. C., 1124
Gibbs, T., 16
Giebink, G. S., 1145
Giedlin, M. A., 849
Gillini, L., 1025
Gilman, R. H., 1139
Giorgi, J. V., 859, 1365
Girón, J. A., 269
Gittens, T., 1382
Glass, R. I., 1139, 1334
Gleich, G. J., 677
Glenn Fowler, M., 567
Glick, J., S148
Gnann, J. W., 9
Goedert, J. J., 1062
Goh, W. C., 548
Goldsmith, C. S., S36
Goldstein, R., 1197
Gomez Morales, M. A., 967
Gonçalves, I., 1502
Gong, J., 1213
Gonser, T., 398
Goodman, K. J., 1319
Goossens, M., 44
Gordeuk, V. R., 283
Gottlieb, G. S., 1157
Götz, F., 1561
Govindarajan, S., 1007
Graham, N. M. H., 1297
Graham, S., 1070
Granade, T. C., 590
Graninger, W., 209
Granowitz, E. V., 1313
Grant, R. M., 1375
Gratten, M., 414
Grau, J. M., 475
Graviss, E., 449
Green, S., 755
Greenberg, H. B., S466
Greenwell-Wild, T., S457
Greenwood, B. M., 287
Greer, P. W., S36, S108, 1469
Greve, B., 980, 1584
Griffin, J. W., 1183
Grimont, F., 1173
Groarke, J. M., 1538
Grosskurth, H., 16
Guerrant, R. L., S331
Guerrero, A., 1553
Guèye-Ndiaye, A., 68
Guigand, L., S54
Guimard, Y., S1, S98, S170, S268
Guina, T., S326
Gulati, S., 124
Gulick, R. M., 808
Guttormsen, H.-K., 142
Guzmán, C. A., 901
Haack, M., 1047
Hack, C. E., 646, 693
Hajjeh, R. A., 449
Halbwachs-Mecarelli, L., 151
Hale-Donze, H., S457
Haley, J. C., 1283
Hall, A. J., 489
Hall, D. B., 1116
Hall, E. R., 107
Hall, G., S489
Hamel, D. J., 68
Hamidur Rahman, A. S. M., 390
Hamill, R., 449
Hammill, H., 567
Han, L. L., 25, 230
Han, Y., 1477
Hanano, R., 455
Handfield, J., 1101
Hannoun, C., 775
Hansen, K. G., 223
Hanson, I. C., 319
Harawa, N., 1388
Harlev, E., 1565
Harlow, S. D., 1580
Harrell, L. J., 1157
Hart, C. E., 871
Haruta, A., 1145
Hashemi, F. B., 924
Hatz, C., S48, 1515
Hatzakis, A., 1062
Hayani, K. C., 584
Hayden, M. K., 163
Haydock, A. K., 1423
Hayes, R., 16
Hazenberg, M. P., 1459
Hazra, S. K., 187
HBY 097/2001 Study Group, 709
Headley, C. M., 653
Heath-Chiozzi, M., 527, 799
Heeren, T. C., 124
Heilmann, C., 1561
Heinzel, F. P., 743
Hellmann, N. S., 1375
Hendricks, K. A., 442, S108
Herbich, K., 980
Herzog, C., 522
Hess, G., 1055
Hewlett, J., 996
Heyderman, R. S., 1288
Heymann, D. L., S60, S76, S139, S283
Hickey, T., 1139
Hickman, M. E., 142
Hietala, S., 1132
Hill, A. V. S., 187, 287, 721
Hill, D., 1382
Hillier, S. L., 1410
Hirsch, C. S., 945
Hirsch, M. S., 345
Hisakawa, H., 1012
Ho, D. D., 527
Ho, T., 1183
Hobbs, M. M., 371
Hochstein, H. D., 1278
Hocini, H., S448
Hodgkins, A. S., 817
Hoesley, C. J., S360
Hoffmeister, A., 690
Hohman, P., 1077
Holding, F. P., 612
Hollingshead, S. K., 414, 627
Holm, A., 637
Holman, R. C., 1469
Holmberg, S. D., 717
Holmes, A., 1197
Holmes, K. K., 729
Hood, A. F., 1283
Hor, L.-I., 275
Horal, P., 775
Horsburgh, C. R., Jr., S461
Horton, R. J., 996
Houghton, R. L., 1226
Hsieh, C.-c., 68
Hsu, H.-M., 367
Hu, J., S413
Huang, M.-L. W., 311
Huang, S. N., 192
Huang, X.-L., 329
Huang, Z. H., 1305
Hube, B., 201
Huggins, J. W., S224, S240, S248
Hultin, L. E., 859
Humar, A., 484
Hunt, N. H., 217
Hurley, A., 527
Husak, S., 1395
Hutagalung, R., 283
Hutchins, W. A., 1433
Hutchinson, D. B. A., 1587
Hutwagner, L., 1416
Hutwagner, L. C., 449
Hwang, L.-Y., 1319
Ichiman, Y., 1030
Illian, A. F., 442
Imaoka, K., S480
Innis, B. L., 755
International Scientific and Technical Committee, S18
Ion-Nedelcu, N., 230
Irving, W. L., 1310
Ishizaki, T., 974
Ison, C. A., 1288
Ison, C., 371
Israel Pediatric *Shigella* Study Group, 1565
Ivanyi, J., 1034
Izopet, J., 1309
Izzo, M. W., 627
Jaax, N. K., S203, S224
Jack, A. D., 489
Jackson, D., S401
Jackson, S., S401
Jackson, T. F. G. H., 460
Jacobson, J. M., 843
Jacobson, L. P., 859

Jadoun, J., 1050
Jahrling, P. B., S108, S148, S192, S203, S224
James, S. A., 1580
James, V., 1310
Jani, D. B., 124
Janoff, E. N., S397, S475
Jarvis, W. R., 442, 751
Jawetz, S. C., 1449
Jensen, A. K., 637
Jenson, H., 1395
Jertborn, M., 107
Jezek, Z., S60
Ji, X., 527
Ji, Y., 1132
Jiang, R.-z., 1197
Jimenez, E., 567
John, C. C., 743
John, G., S401
John Albert, M., 390
Johnson, J. L., 945
Johnson, K. M., S139, S287
Johnson, T. D., 859
Johnston, D. M., 1259
Johnston, S. L., 677
Jol-van der Zijde, C. M., 31
Joly, P., 1
Jones, G. J., 558
Jones, I., S489
Jónsdóttir, K. E., 223
Jurriaans, S., 790
Kaboré, A. F., 1162
Kabwau, J., S274
Kagnoff, M. F., S444
Kaku, M., 1030
Kalayanarooj, S., 755
Kalish, M. L., 590
Kalkoa, M., 974
Kallas, E. G., 1124
Kalongi, Y., S15
Kamal, S. M., 382
Kaneko, A., 974
Kaneko, O., 974
Kanki, P. J., 68
Kanzake, L., S15
Karavellas, M. P., 697
Karch, H., 115, 1274
Karchmer, T., 548
Karpas, A. B., 1565
Kasper, D. L., 142, 1030
Kasper, L. H., 467
Kato, N., 1245
Katoch, K., 1034
Katshitshi, J., S36
Katsoulidou, A., 1062
Katwiki, K. R., S1, S268
Katz, B. P., 1283
Katzenstein, D. A., 1382
Kaufmann, S. H. E., 455
Kawabata, S., S480
Kawase, H., 508
Kay, B. A., 382
Keeling, M. E., S408
Keet, I. P. M., 254
Kell, W. M., S203
Kelley, M., S108
Kersten, M. J., 240
Kerstiens, B., S76, S263
Kessler, H., 799
Keusch, G. T., 503
Khamboonruang, C., 59
Khan, A. S., S24, S28, S36, S76, S87, S92, S98, S102, S115, S164, S170, S177, S235
Kibadi, K., S1, S11, S13, S18, S268
Killian, S., S98
Kilmarx, P. H., S76
Kim, J. H., 337
Kim, W.-J., 163
Kim, Y., 1145
Kimura, M., 1297
Kind, C., 705
King, A. J., 503
King, C., 996
King, C. L., 743
Kipasa, M. A., S1, S11, S18, S259, S268
Kiyono, H., S480
Kiyungu, C., S259
Klausner, J. D., 729
Klebanoff, S. J., 653
Kleeberger, C., 1365
Kleim, J.-P., 709
Klein, M. R., 240
Klein, N. J., 1288
Klimov, A., 1132
Knayer, U., 398
Knecht, H., 240
Knight, J. C., 287
Knight, S. T., 954
Knook, D. L., 31
Kobayakawa, T., 974
Koch, K., 1557
Koech, D., 996, 279
Koenig, S., 619
Koenig, W., 690
Kojima, S., 1515
Kolesnikova, L. V., S199
Kollaritsch, H., 522
Kombe, Y., 996
Konde, M. K., S274
Könen-Waisman, S., 403
Kong, L. K., 1157
Konya, J., 701
Koot, M., 254
Korber, B. T., 319
Korelitz, J., 567
Koster, F. T., 295
Kotler, D. P., S454
Koup, R. A., 1310
Kovacs, A., 567
Kovacs, J. A., 192, 849
Kozlowski, P. A., S493
Kraus, T., 1047
Krause, P. J., 931
Krautheim, A., 705
Krebs, J. W., S155, 1469
Kreiss, J., S401
Kremsner, P. G., 209, 980, 1042, 1584
Kresina, T. F., S391, S392
Kreutzer, K., 714
Krohn, M. A., 1410
Krol, A., 825
Krone, M., 548
Ksiazek, T. G., S15, S24, S28, S36, S76, S87, S92, S98, S102, S108, S115, S148, S155, S164, S170, S177, S192, S274
Kubota, M., S480
Kudoyarova-Zubavichene, N. M., S218
Kuehne, A., S148
Kuhn, L., 52
Kulasegaram, R., 234
Kully, C., 705
Kun, J. F. J., 1042
Kunz, C., 522
Kurane, I., 295, 755
Kurashige, T., 1012
Kurimoto, M., 646
Kuritzkes, D. R., 799, 808
Kuvula, K. J., S1, S11, S13, S18, S268
Kvale, D., 74
Kwiatkowski, D., 287
Lacey, C. J. N., 612
Lachenauer, C. S., 1030
Lacy, D., S305
Lagaye, S., 44
Lal, A. A., 279, 1218
Lalonde, R., 1101
Laman, J. D., 1459
Lambert, G., 52
Lambert, J. S., 567
Lambert, P.-H., 1326
Lamson, M., 1116
Lamy, P. D., 92
Landay, A., 799
Lane, H. C., 849
Lange, J. M. A., 254, 790
Langendam, M. W., 825
Lansoud-Soukate, J. M., S65
La Rosa, G., 967
Laurentia, V., 230
Lauw, F. N., 646
Lavreys, L., S401
Lawrence, J., 249, 1356
Le Guenno, B., S48, S54, S76, S120
Leary, T. P., 1242
Lederman, M. M., 799, 843
LeDuc, J. W., February supplement, ix, S224
Lee, J. S., 538
Lee, S.-C., 367
Lee, Y. J., 107
Lefrère, J.-J., 783
Lehman, L. G., 980, 1584
Lehner, T., S480, S489
Leiby, D. A., 1226
Lein, D., 637
Leirs, H., S155
Lekstrom-Himes, J. A., 1077
Lell, B., 980, 1042, 1584
Leman, P. A., S177
Lenkowski, P. W., Jr., 460
Lennette, E. T., 237
Lennox, J. L., 871
Lenoir, G., 151
Leonard, J. M., 527, 799
Lepage, J. P. M., S65
Lepera, A., 1534
Lepore, T., 931
Lerable, J., 783
Leroy, E. M., S65
Lesens, O., 1254
Leuther, M., 1055
Levesque, B., 37
Levi, M., 646
Levin, M., 1288
Levine, O. S., 101
Levy, J. A., 237
Lew, R., 755
Lewin, J., 352
Lewis, J., 859
Lewis, P., S401
Li, L., S436
Li, S., 1132
Li, Y., 600
Li, Z., 907
Liabakk, N.-B., 74
Liebmann, J. M., 329
Lien, E., 74
Liles, W. C., 1038, 1301
Lima, A. A. M., S331
Lin, J., 1145
Lin, S.-R., 367
Lindbäck, S., 1549
Lindh, M., 775
Linnau, K. F., 747
Lipton, J., 484
Liska, V., S408
Liu, C., 1132
Liu, C. Y., 996
Livingston, J., 434
Liz, J., S148
Lloyd, E. S., S15, S36, S274
Lockhart, L. A., 460
Locksley, R. M., S305
Lodes, M. J., 1226
Lomakina, S., 1416
Long, E. M., S401
Looareesuwan, S., 283, 747
Lopez, F. A., 670
Louie, L., 892
Louie, M., 892
Lovgren, M., 892
Low, J. L., 677
Loyens, M., 83
Lu, C.-F., 367
Luchko, S. V., S199
Luckner, D., 980, 1042, 1584
Ludovisi, A., 967

Ludwig, G., S155
Ludwig, S. L., 1531
Luque, A. E., 1405
Lusiama, N., S15
Luty, A. J. F., 980
Luzuriaga, K., 319
Lyerly, D. M., 460
Mabey, D., 16
Mac Kenzie, W. R., S92
MacDonald, D., 1070
MacDonald, D. M., 686
Macdonald, J. C., 697, 1249
MacDonald, K., 513
MacDonald, K. S., 484
Mack, D., 1561
Macken, C., 319
Madoff, L. C., 1030
Madzime, S., 1382
Maeda, A., 1012
Mahanty, S., 1502
Mahmoud, A. A. F., 743
Maine, N., 489
Majadly, F., 1565
Maldonado, Y., 1382
Malech, H. L., S318
Manalo, D. L., S115
Mandaliya, K., S401
Manglicmot, J., 670
Manguindula, L., S274
Mann, B. J., 460
Mapanda, B. B., S1, S268
Margolis, H. S., 37
Mariotti, M., 783
Mark, D., 1388
Markee, J., 548
Markowitz, M., 527
Marlink, R., 68
Marshall, K. L., S102
Marti, D., 1004
Martin, D. H., 1423
Martin, H., Jr., S401
Martin, I., 371
Martin, J., 44
Martin, L. N., S408
Martin, M. L., S177
Martinez, M. B., 269
Martinez-Beltran, J., 1553
Martinez-Picado, J., 345
Maruyama, T., S235
Mascie-Taylor, C. G. N., 187
Massamba, M., S1, S11, S13, S18, S268
Mastro, T. D., 590
Masur, H., 849
Mathieson, B., S392
Mathieson, B. J., 567
Matlashewski, G., 1485
Matousek, P., 980
Matsumoto, A., 1055
Matthews, S., 234
Matthys, F., S263
Mauclère, P., 44
Maupin, G., S148
May, J., 1042
Mayatepek, E., 714
Mayaud, P., 16
Mayer, K., 1310
Mayumi, M., 1245
Mazzulli, T., 484
Mbizvo, M., 1382
M'bopi Kéou, F.-X., 44
Mbori-Ngacha, D., S401
MBoup, S., 68
McAdam, K. P. W. J., 721
McClelland, R. S., 1157
McClernon, D. R., 799
McClure, H. M., S408
McCormick, J. B., S60
McElrath, M. J., 548
McGarvey, S., 996
McGeer, A., 484
McGhee, J. R., S480
McGinn, T., 600
McGuire, W., 287
McIntosh, K., 1395
McKeating, J. A., 859
McKechnie, D. B., 1469
McKhann, G. M., 1183
McMahon, D. K., 329
McMahon, F. G., 1278
McNeill, P. D., 1226
McQuain, C., 240
McQuillen, D. P., 124
Mead, P., 1416
Meals, E. A., 939
Medina, E., 901
Mehlin, C., 653
Meier, F., S139
Meij, P., 1108
Meijer, C. J. L. M., 1108
Meldorf, M., 548
Melief, M.-J., 1459
Mellors, J. W., 329
Melpolder, J. C., 1055
Mendy, M., 489
Meng, G., S436
Menu, E., 44
Merchant, S. N., 264
Merigan, T. C., 249, 709, 1356
Mermin, J. H., 1416
Merrill, D. P., 345
Merriweather, A., 1577
Mertz, K. J., 1423
Merville, P., 1
Meshnick, S. R., 1580
Mesola, V. P., 729
Messner, H., 484
Mestecky, J., S470
Metcalf, J. A., 849
Meyer, C. G., 1042
Meyer, W. A., III, 567
Michel, P., 1
Michel, U., 1557
Middeldorp, J. M., 1108
Migot-Nabias, F., 980
Mikyas, Y., 1388
Milleliri, J. M., S65
Miller, B., S148
Miller, C. J., S413, S480
Miller, E., 1569
Miller, M. D., 92
Miller, S. I., S326
Mills, J. N., S155
Miner, R., 1352
Minton, E. J., 1310
Mintz, E. D., 1416
Miranda, M. E., S115, S164
Miranda, P., 1502
Miron, D., 1565
Misore, A., 1218
Mitchell, E., S489
Mitsuyasu, R. T., 843
Miyakawa, Y., 1245
Miyoshi, I., 1046
Mo, D., 1132
Mock, P. A., 590
Mofenson, L. M., 567
Mokili, J. L. K., 1070
Molinari, G., 901, 1049
Molrine, D. C., 513
Monath, T. P., S127
Monroe, S. S., 1334
Montano, M., 68
Montefiori, D. C., 1264
Monteiro, E. F., 612
Montenegro, S. M. L., 1502
Montgomery, A. B., 1190
Montoya, J., 1356
Montoya, J. M., 295
Mooi, F. R., 915
Moore, J. P., 527
Moore, J. M., 1218
Moran, A. P., 1183
Morand-Joubert, L., 783
Moreau, J.-F., 1
Morelli, L., 201
Mori, M., 295
Morris, R., 1569
Morrow, R. H., 1515
Morse, S. A., 1423
Mortagy, A. K., 382
Mosha, F., 16
Moss, B., 1345
Mostad, S., S401
Mourad, A. S., 382
Moury, F., 1173
Mouton, Y., 83
Moye, J., Jr., 567
Moyenul Isalm, M., 390
Muerhoff, A. S., 1242
Mugerwa, R., 945
Mugyenyi, P., 945
Muhungu, G. L., S92
Mukundu, W., S11
Mukunu, R., S28, S87, S177
Mulato, A. S., 92
Müller, F., 74
Mullington, J., 1047
Multicenter Hemophilia Cohort Study, 1062
Munguti, K., 16
Munjoma, M., 1382
Muñoz, A., 1365
Munoz, S. J., 1007
Mupapa, K. D., S1, S11, S13, S18, S268
Murphey-Corb, M., S408
Murphy, B. R., 1345
Murphy, J. R., 382
Murphy, R. L., 808, 1116
Musey, L., 548
Mushahwar, I. K., 1242
Mustafa, A. S., 637
Muyembe-Tamfum, J. J., S1, S8, S11, S13, S18, S28, S60, S76, S259, S283
Mwanza, K., S15
Myers, M., 1116
Nabeth, P., S76
Nabias, R. J., S65
Nachamkin, I., 1183
Nadol, J. B., Jr., 264
Naficy, A., 107, 382
Nagelkerke, N. J. D., 915
Nagy-Agren, S. E., 493
Nahlen, B., 279
Nahlen, B. L., 1218
Nainan, O. V., 37
Nakatani, K., 508
Nam, J.-m., 1077
Napodano, J., 460
Nasirul Islam, K. M., 390
Natpratan, C., 59
Nau, R., 1557
Nauta, K., 790
Navas, E., 1553
Ndaberey, D. E., S1, S11, S13, S268
Ndambe, R., S98
Ndambi, R., S8, S92, S274
Ndinya-Achola, J., S401
NDoye, I., 68
Nduati, R., S401
Neal, K. R., 1310
Nedrud, J. G., 725
Neilson, J., S401
Nelson, K. E., 59, 1004
Nelson, S., 1441
Nemo, G. J., 567
Nesburn, A. B., 1086
Nesheim, S. R., 52
Ness, P. M., 1055
Netesov, S. V., S218
Neutra, M. R., S441, S493
Neves, O., 475
Ngoc, M. T., S65
Nguyen, T. N., 1326
Nichol, S. T., S28, S76, S164, S170
Nichols, C. M., 763
Nicholson, M. A., 1183
Nimmannitya, S., 755
Nisalak, A., 755
Nishanian, P., 843
Nixon, D. F., 527
Nkuku, O. B., S76, S268

Noah, D. L., S92
Noel, J. S., 1334
Nøkleby, H., 223
Nolan, R., 1197
Nolte, K. B., 295
Nordøy, I., 74
Norkrans, G., 775
Norman, J. E., 295
Ntando, E., S15
Nugent, R., 567
Nussenzweig, R. S., 980
Nutman, T. B., 738
Nyirenda, T., 1580
Obasi, A., 16
Obiang, P. I., S65
O'Brien, S. J., 1004
Odhiambo, O., 996
Oette, D., 709
Oftung, F., 637
O'Grady, N. P., 136
Ogunrinade, A., 1577
Ohtsuka, H., 1030
Okamoto, H., 1245
Okanoue, T. , 291
Okwera, A., 945
Olds, G. R., 996
Olobo, J., 637
Olson, J. G., 1469
Olveda, R., 996
Olver, W. J., 1312
O'Malley, P., 717
O'Neill, T., 612
Onori, A. M., 967
Orago, A. S. S., 279
Orbach, M. J., 518
Orenstein, J. M., S457
Orsborn, K. I., 518
Ortega, Y. R., 1139
Ortona, L., 1025
O'Shea, S., 234
Oshitani, H., 522
Osmond, D., 237
Ossondo, M., 497
Ostrowski, S. R., S281
O'Sullivan, M. J., 567
Othoro, C., 279
Ottesen, E. A., 738
Otto, G., 172
Otto, K. L., 1190
Ouma, J., 996
Ouma, J. H., 743
Overbaugh, J., S401
Owens, B., 859
Ozden, S., 497
Paddock, C. D., 1469
Pahwa, S., 576
Palmer, K. L., 1283
Palumbo, P., 52
Palumbo, P. E., 576
Panteleeff, D., S401
Paoletti, L. C., 142, 1030
Paparella, M. M., 1145
Papi, A., 677
Papia, G., 892
Pappas, P. G., 449
Para, M. F., 245
Paradis, D., 37
Parashar, U. D., 1139
Parekh, B., 590
Parkin, N. T., 1375
Parkinson, A., 101
Parkinson, A. J., 414
Parraga, I., 996
Parren, P. W. H. I., S235
Partanen, J., 682
Passwell, J. H., 1565
Paul, T. R., 954
Peacock, S., 291
Peakman, M., 1288
Pearson, S., S108
Pecor, J., S148
Peddis, G., 1007
Pediatric AIDS Clinical Trials Group Protocol 185 Team, 567
Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV-1 Infection (P^2C^2 HIV) Study Group, 1395
Peeling, R. W., 180
Peltola, H., 223
Peng, G., S457
Peng, T., 518
Perdue, M. L., 1132
Perez, J., 1139
Perinatal AIDS Collaborative Transmission Study, 52
Perkins, B. A., 101
Perkins, M. D., 1259
Perng, G.-C., 1086
Perrin, L., 705
Perry, H. N., S274
Peruski, L., 107
Peruski, L. F., 382
Pesano, R., 1356
Peters, C. J., February supplement, ix, S1, S24, S28, S36, S76, S87, S92, S98, S102, S108, S115, S148, S155, S164, S170, S177, S188, S192, S224, S235, S274
Peters, P., 945, 996
Peters, R. L., S108
Petersdorf, R. G. , March supplement, iv, March supplement, v, S289, 1317
Petersen, L. R., 1274
Petit, J.-C., 783
Petri, W. A., Jr., 460
Petropoulos, C. J., 1375
Pevear, D. C., 1538
Phair, J. P., S384, 859
Pham, M. H., 442
Phillips, S. K., 590
Pilcher, C. D., 1259
Pilot-Matias, T. J., 1242
Ping, L., S489
Pingel, S., S305
Pinner, R. W., 449
Piscitelli, S. C., 849
Pissard, S., 44
Pitrak, D. L., 584
Pitt, J., 1395
Placido, R., 832
Plaeger, S., 1388
Platt, R., 434
Ploplis, V. A., 907
Plotnicky-Gilquin, H., 1326
Plummer, D. J., 697
Polis, M. A., 849
Pollmächer, T., 1047
Pope, M., S427
Popek, E., 319
Popovici, F., 230
Porat, R., 1313
Porter, W., 931
Porwancher, R., 1021
Poss, M., S401
Posteraro, B., 1025
Potaux, L., 1
Power, U. F., 1326
Pozio, E., 967
Pratt-Palmore, M., 871
Preas, H. L., 1048
Preas, H. L., II, 136
Prendergast, M. M., 1183
Prescott, L. E., 1070
PRIDE Study Group, 107
Prince, A., 1449
Prud'homme, H., 37
Pucak, G., S108
Purcell, R. H., 1007
Quan, J. M., 1190
Que, J. U., 522
Quigley, M., 16
Rabbani, G. H., 390
Raborn, G. W., 303
Racz, P., 527
Rajan, S., 1449
Rakwar, J., S401
Ram, S., 124
Ramirez, B., 996
Ramon, R., 1565
Ramsey, B. W., 1190
Rank, R. G., 954
Rao, M., 107, 382
Rappaport, J. M., 264
Raskino, C., 576
Ratto-Kim, S., 337, 817
Ravn, P., 637
Ray, B. J., 442
Ray, N. B., S408
Reardon, E. S., 725
Reda, D., 136
Redfield, R. R., 337
Reed, S. G., 1226
Rees, A. D., 558
Reeve, P., 996
Reichelderfer, P., 567
Reichman, R. C., 1405
Reiner, S. L., 1573
Reingold, A., 449
Reiss, P., 254, 790
Reiter, P., S148
Relman, D. A., 670
Remarque, E. J., 31
Remick, D., 738
Renaut, A. A., S65
Rench, M. A., 142
Rensink, I., S235
Rentenaar, R. J., 693
Retuya, T. J., S115
Reynolds, L. D., 1226
Rice, P. A., 124
Richardson, B., S401
Richmond, P., 1569
Riddler, S. A., 329
Rieß, G., 709
Rihkanen, H., 682
Rijkers, G. T., 1152
Riley, M., 1197
Rinaldo, C. R., Jr., 329
Rinkaew, M., 59
Rizvi, T. A., S408
Robb, M. L., 59, 817
Robbins, C. B., S139
Robbins, J. B., 1565
Robbins, R., S148
Roberts, J. S. C., 612
Roberts, L., 1416
Robinson, D. A., 414
Rocchi, G., 832
Roces, M. C., S115
Rodier, G. R., S76, S283
Rodriguez, L. L., S28, S170, S235
Rodriguez, M. E., 423
Roebuck, K. A., 924, S444
Roels, T. H., S92, S102
Rogenmoser, P., S48
Rolka, H. R., S92
Rollin, P. E., S1, S15, S28, S36, S76, S87, S98, S108, S115, S164, S177, S188, S192, S274
Romano, J. W., 600
Romano, L., 361
Romanus, V., 223
Romero, S., 1139
Roongpisuthipong, A., 590
Root, R. K., March supplement, iv, March supplement, v, S342, 1038, 1301
Rooth, I., 989
Rosenkrands, I., 637
Ross, B., 1416
Rothel, J. S., 1297
Rothenbacher, D., 398, 690
Rothman, A. L., 295, 755
Rothrock, G., 449
Roudot-Thoraval, F., 783
Rousseau, F., 799
Rowe, A. K., S28, S170, S177
Rowe, N. H., 303

Roy, S., 187
Rubin, R., 1007
Rudin, C., 705
Rugpao, S., 59
Ruiz, N., 337
Ruiz-Tagle, A., 269
Rumpold, H., 747
Rupp, M. E., 1561
Ruprecht, R. M., S408
Ruti, K., S139
Ruwende, C., 721
Ryabchikova, E. I., S199
Ryan, J., 734
Ryan, R., 931
Sabin, C. A., 234
Sack, D. A., 1515
Sadek, R. F., S24
Sadler, F., 1569
Safwat, M., 107
Saha, B., 187
Samanta, S., 734
Samaridden, A., 1416
Samra, Y., 513
Samten, B., 1213
Sanchez, A., S76, S108, S115, S164, S170, S177, S235
Sande, M. A., S387
Sanders, L. A. M., 423, 1152
Sands, K., 434
Sang, D. K., 743
Sanglard, D., 201
Sanguinetti, M., 1025
Sankalé, J.-L., 68
Sanneman, T. C., S475
Sanni, L. A., 217
Sapan, C. V., 567
Saracino, A., 1534
Sarin, K. K., 1034
Savarino, S. J., 107, 382
Sax, P. E., 345
Scamurra, R. W., S475
Scarlatti, G., 44
Schäfer, W., 201
Schapiro, J., 1356
Schapiro, J. M., 249
Scheer, S., 717, 1264
Scheffler, L., 1449
Scheid, A., 1046
Schellekens, P. T. A., 693
Schinazi, R. F., 871
Schinkel, J., 825
Schmaljohn, C., S248
Schmid, D., 209, 980
Schmidt, H., 115, 1557
Schmidt, T. M., 670
Schmidt-Ott, R., 980, 1584
Schneerson, R., 1565
Schneider, O., 1557
Schnell, C., 871
Schoenbaum, E., 52
Schriefer, M. E., 931
Schrijver, I. A., 1459
Schuchat, A., 449, 751
Schuijtemaker, J., 790
Schuitemaker, H., 254, 825
Schulz, T. F., 1016, 1534
Schutzbank, T., 576
Scott, G. R., 686
Scott, G., 567
Séguin, R., 467
Seki, S., 508
Sekine, I., 508
Sekirassa, Z., 16
Sela, S., 1050
Seminario, M. C., 677
Sengupta, U., 1034
Sergeyev, N. N., S218
Sermet-Gaudelus, I., 151
Sexton, D. J., 1157
Shadman, A., 1352
Shaffer, N., 590
Shapiro, A. M., 1249
Shapiro, C. N., 37
Shawar, R. M., 1190
Shearer, W., 1395
Shearer, W. T., 567
Shebib, N., 763
Sheikh, K., 1183
Sher, A., 1502
Sherman, K. E., 1062
Shevy, D. S., 513
Shieh, W.-J., S15, S36, S274
Shih, J. W. K., 1055
Shih, R., 859
Shimada, J., 1030
Shimoda, A., 1007
Shiuan, K., 259
Shufelt, C. L., 697
Shugars, D. C., S431
Shute, J. K., 677
Siber, G. R., 513
Siby, T., 68
Siegrist, C.-A., 1326
Sikand, V. K., 931
Simard, M., 1162
Simmonds, P., 686, 1070
Simonds, R. J., 52
Simonis, T., 1077
Simons, J. N., 1242
Simor, A. E., 892
Simpson, D., S108
Singh, M., 1034
Singleton, J., Jr., 1469
Singleton, R., 101
Sinsheimer, J. S., 1388
Siriwasin, W., 590
Sitz, K. V., 337, 817
Skeiky, Y. A. W., 1226
Slanina, S. M., 1086
Sleath, P. R., 1226
Smadja, D., 497
Smeaton, L., 808
Smillie, D., 1310
Smith, A. L., 1190
Smith, D., 1310
Smith, H. V., 670
Smith, I. L., 1249
Smith, N. A., 234
Smith, P. A., 1310
Smith, P. D., S397, S436
Snounou, G., 989
Sommadossi, J.-P., 808, 1116
Sönnerborg, A., 1542
Soong, S. J., 9
Sorial, V., 192
Soto, A., 1557
Soucier, H., 1124
Spaeny, L. H. A., 693
Sparling, P. F., 371
Spear, G., 799
Spear, G. T., 924
Speck, R., 249
Spector, S. A., 576, 1249
Speelman, P., 646
Speert, D. P., 1449
Spinola, S. M., 1283
Spritzler, J., 799
Spruance, S. L., 303
St. Louis, P., 484
Stamm, W. E., S380
Steben, M., 1254
Steele, K. E., S203
Steinbach, S., 1197
Steiner, C., S120
Steiner, T. S., S331
Steingrover, R., 790
Steinhoff, M. C., 414
Stek, A., 567
Steketee, R. W., 52
Stempien, M. J., 1352
Stephens, D. S., 449
Stephens, H., 59
Sterling, C. R., 1139
Stevens, D. L., S366, 1293
Stevens, G., S24
Stiehm, E. R., 567
Stocker, R., 217
Stoll, A., S48
Stoltz, D. A., 1441
Straus, S. E., 1077
Suarez, J.-R., 709
Subbarao, K., 1132
Subbarao, S., 590
Suffredini, A. F., 136, 1048, 1278
Suleiman, J., 1591
Sullivan, A. D., 1580
Summer, W. R., 1441
Sundaram, S., 503
Sundstrom, J. B., S188
Suntayakorn, S., 755
Surachno, J., 693
Suzuki, H., 522
Svanborg, C., 172
Svennerholm, A.-M., 107
Svensson, Å., 989
Swanepoel, R., S36, S76, S98, S177, S188
Swearengen, J. R., S224
Swiss Collaborative "HIV and Pregnancy" Study, 705
Symonds, W., 1375
Szczeniowski, M. V., S139, S283
Szczeniowski, M. Y., S60
Taddei, C. R., 269
Takechi, M., 974
Takeshita, S., 508
Talal, A., 527
Talay, S. R., 901
Talbot, J., 892
Tan, D., 1055
Tan, M., 1395
Tan, S.-J., 1352
Tang, H. B., 1449
Tangy, F., 497
Tarr, P. I., 115
Taupin, J.-L., 1
Taylor, D. N., 1139
Taylor, J. M. G., 843
Taylor, R., 1197
Taylor, T., 1580
Tedeschi, R., 1016
Teixeira, K. M., 1502
ten Berge, I. J. M., 693
Tencer, K., 337
Tengelsen, L. A., 230
Tenner-Racz, K., 527
Teran, L. M., 677
Tersmette, M., 254
te Velde, A. A., 646
Tevi Benissan, C., S65
Thauvin, M., 783
Thea, D. M., 52
Thibodeau, E. A., 303
Thio, C. L., 1004
Thior, I., 68
Thomas, C., 449
Thomas, D. L., 1004
Thomas, J. C., 371
Thomas, M. G., 291
Thompson, C. H., 701
Thompson, H. S. G., 612
Thurn, J. R., S475
Thursz, M., 721
Tipple, M. A., S281
Todd, J., 16
Toma, E., 1101
Tomoda, T., 1012
Tomori, O., S76, S98
Toossi, Z., 945
Torriani, F. J., 697
Totten, P. A., 1423
Trabulsi, L. R., 269
Trappier, S. G., S108, S164, S170,
Treadwell, T. A., 1469
Treanor, J. J., 1124
Tremblay, C., 345
Trevejo, R. T., 931
Triozzi, P. L., 245
Tropea, M., 136
Truong, M.-J., 83
Tsai, T. F., 230, 522
Tshioko, F. K., S36, S76, S98, S274

Tshisuaka, M., S15
Tsoukas, C. M., 538, 1254
Tukadila, A. M., S8
Tung, R., 808
Turell, M., S148
Turner, A. K., 124
Turner, J. S., 414
Turner, R. E., 192
Uccella, I., 832
Udhayakumar, V., 279, 1218
Uhr, M., 1047
Ukita, M., 1245
Ulphani, J. S., 1561
Ulrich, M. A., 1477
Underwood, J. C. E., 1310
Ung, H., 1183
Unnasch, T. R., 1577
Vaheri, A., 682
Valdezate, S., 1553
Valensin, P. E., 361
Vambutas, A., 1145
van Baarle, D., 240
van Burik, J.-A. H., 1038, 1301
VanCott, T. C., 59, 1310
Van Dalfsen, J. M., 1190
Van den Enden, E., S1, S268
van den Herik-Oudijk, I. E., 661
Van de Perre, P., S405
van der Groen, G., S139
van der Heide, H. G. J., 915
van der Pol, W.-L., 423
van der Poll, T., 646
van der Vliet, H. J. J., 693
van Deventer, S. J. H., 646
van de Winkel, J. G. J., 423, 661
van Dissel, P., 1108
Vandivier, R. W., 136
Van Dyke, R. B., 319
Vanham, G., 945
van Leeuwen, R., 254, 790
van Loo, I. H. M., 915
van Oers, R., 240
van Sorge, N. M., 661
van Spriel, A. B., 661
van Strijp, J. A. G., 661
van Tol, M. J. D., 31
Vaughn, D. W., 755
Vendetti, S., 832
Venturi, G., 361
Verchueren, E., S274
Verhoef, J., 915
Vernant, J.-C., 497
Verral, S. C., 584
Vervoort, M. B. H. J., 1108
Vesanen, M., 527
Viera, A. J., 751
Vilé, H. A., 661
Villar, R., 1416
Villaseñor-S, A., 1293
Villinger, F., S188
Vinel, J.-P., 1309
Vineyard, G., 434
Virus Study Teams, Ebola, S139
Viscarello, R. R., 319
Visco-Comandini, U., 1542
Vittinghoff, E., 717
Vizzard, J., 1549
Vlahov, D., 1004, 1297
Volberding, P. A., 1375
von Giesen, H.-J., 714
von Hoegen, P., 558
von Reyn, F., 637
Voorhorst-Ogink, M. M., 1152
Wagatsuma, Y., 1515
Wahl, S. M., S397, S457
Waite, D. C., 295
Wakiguchi, H., 1012
Wakil, A. E., S305
Wald, A., 1077
Walker, B. D., 345
Walker, F., S120
Walker, R. E., 849
Walling, D. M., 763
Walsh, E. E., 1268
Wang, S.-T., 275
Wang, Y., S489
Wanner, P., 690
Warren, T., 1077
Watts, D. H., 653
Weaver, S. C., 763
Webb, P. A., S139
Weber, J., 558
Webster, C., 1312
Webster-Cyriaque, J., 763
Wechsler, S. L., 1086
Weeda, M., 790
Weedon, J., 52
Wei, Q., S418
Wei Ning, C., 259
Weinstein, R. A., 163
Weiss, H. L., 9
Weiss, R. A., 234
Welch, M., S401
Wellmer, A., 1557
Weniger, B. G., 590
Wenisch, C., 747
Wertheim, P. M. E., 693
Wessels, M. R., 142
West, C. P., S192
Westendorp, R. G. J., 31
Westerink, M. A. J., 1433
Weston, V., 1312
Wever, P. C., 693
Weverling, G. J., 790
Whalen, C., 996
Whalen, C. C., 743
Whitby, D., 234
Whitehouse, J., 567
Whitley, R. J., 9
Whittington, W. L., 729
Whittle, H. C., 489, 721
Wicher, K., 1206
Wicher, V., 1206
Wickings, E. J., S65
Wickremasinghe, R. G., 352
Widmayer, S. M., 319
Widmer, A., S48
Wiedermann, G., 522
Wierzba, T. F., 107, 382
Wilairatana, P., 283
Wiley, D. J., 859
Wilkinson, K. A., 1034
Wilkinson, R. J., 1034
Willheim, M., 209
Williams, A. J., S28, S170, S177
Williams, R. J., S108
Williams, S. B., 1310
Winkler, I., 709
Winkler, S., 209
Winslow, D., 1356
Winter, J., S188
Winters, M., 709, 1356
Winters, M. A., 249
Wit, F. W. N. M., 790
Witko-Sarsat, V., 151
Wiznia, A., 319
Wolbink, A. M., 693
Wolinsky, S., 319
Wolinsky, S. M., 859
Wondwosson, H., 637
Wong, D. C., 1007
Wong, J. T., 345
Woodcock, S. A., 68
Woods, L., 1132
Woollen, N., S155
Wright, T. C., 871
Wu, G., 996
Wu, H., 799
Wu, J. S., 1319
Wyatt, L. S., 1345
Wyers, M., S54, S120
Wynn, T. A., 1502
Wyrick, P. B., 954
Yamamoto, M., 508
Yaman, M., 527
Yang, Z., 1213
Yannakis, C. M., 538
Yasui, K. , 291
Yeh, C., 670
Yerly, S., 705
Yi, Y., S422
Yokoyama, W., 1012
Yoo, D., 1183
Yoshioka, S., 508
Young, N. L., 590
Young, N. S., 619
Youssef, F., 107
Yue, L., S418
Yun, Z., 1542
Zago, A. M., 1259
Zaki, S. R., S15, S36, S76, S108, S188, S274, 1469
Zazzi, M., 361
Zegers, B. J. M., 1152
Zeh, J., 311
Zelezny, R., 714
Zhang, E., 68
Zhang, M., 1213
Zhang, P., 1441
Zhang, Z.-X., S240
Zijenah, L., 1382
Zimmerman, P. A., 59
Zolla-Pazner, S., 1365
Zolopa, A., 1356

Subject Index

Abscess, liver, amebic, T lymphocyte suppression in, gerbil model, 1495
Acetate, for shigellosis, rabbit model, 390
Acquired immunodeficiency syndrome (*See* Human immunodeficiency virus infection)
β-Actin, in *Cryptosporidium parvum* infections, in immunodeficiency vs. immunocompetency, 967
Acute respiratory distress syndrome, pathogenesis, 295
Acyclovir, for herpes zoster, pain persistence and, 9
Adefovir, for HIV infection, reverse transcriptase mutations and, 92
Adenocarcinoma, gastroesophageal, epidemiology, vs. *Helicobacter pylori* decline, 1522
S-Adenosylhomocysteine hydrolase inhibitors, for Ebola virus infections, mouse model, S240
Adenovirus, infections, in military population, 1530
Adhesins, intercellular, *Staphylococcus epidermidis*, in biofilm formation, 1560
Adhesion molecules, in neutrophil response to *Neisseria meningitidis*, 1288
Adrenal gland, Ebola virus infection, guinea pig model, S203
Age, cytokine production and, in *Plasmodium falciparum* malaria, 209
AIDS (*See* Human immunodeficiency virus infection)
Albendazole, with praziquantel, for schistosomiasis with geohelminthic infections, 996
Alcaligenes xylosoxidans, resistance in, tobramycin, 1190
Alcohol intoxication, pulmonary endotoxin response in, granulocyte colony-stimulating factor effects on, rat model, 1441
Alhydrogel, in human papillomavirus vaccine preparation, 612
Amebiasis
  T lymphocyte suppression in, gerbil model, 1495
  virulence factors, 460
Amnionitis, streptococci group B, 1410
Amoebic encephalitis, granulomatous, *Balamuthia mandrillaris*, 1305
Amoxicillin, prophylactic, for *Salmonella* bacteremia, in HIV infection, 1552
Ampicillin, for hearing loss prevention, in *Streptococcus pneumoniae* meningitis, rabbit model, 264
Amprenavir, for HIV infection, 808
Anemia
  in hookworm infestation, platelet inhibition in, 1235
  in malaria
    interleukin-10/tumor necrosis factor-α ratio in, 279
    tumor necrosis factor promoter alleles in, 287
Animal models
  amebiasis pathogenesis, gerbil, 1495
  Candida albicans vaccination, mouse, 1477
  Candida albicans vaginitis, rat, 201
  Chlamydia trachomatis major outer membrane protein antibody response, mouse, 180
  chronic granulomatous disease gene therapy, mouse, S318
  colony-stimulating factor effects, S342
  Cyclospora-like organisms, baboon, 670
  Ebola virus infections (*See also* Ebola virus infections, in primates)
    guinea pig, S203, S218
    treatment
      monkey and guinea pig, S224
      mouse, S240, S248
  Entamoeba histolytica virulence, gerbil, 460
  group A streptococci skin infections, mouse, 907
  hearing loss in pneumococcal meningitis, rabbit, 264
  Helicobacter antibody response, mouse, 725
  hepatitis C virus transmission, chimpanzee, 1007
  herpes simplex virus type 1, ocular, interleukins in, mouse, 1086
  human immunodeficiency virus infection
    dendritic cells in, primate, S427
    macaque, 600
    mucosal immunity, macaque, S480
    oral transmission, primate, S408
    rectal transmission, chimpanzee, S418
    vaccination, macaque, S480, S489
    vaginal transmission, primate, S413
  influenza virus vaccination, ferrets and chickens, 1132
  interleukin-12-induced inflammation, chimpanzee, 646
  Leishmania susceptibility, mouse, S305
  leishmaniasis treatment with immunomodulators, mouse, 1485
  Lyme disease, mouse, 734, 1572
  malaria pathogenesis, mouse, 217
  parainfluenza virus vaccination, monkey, 1345
  pneumococcal otitis media, rat, 1145
  Pneumocystis carinii major surface glycoprotein characterization, rat, 192
  Pneumocystis carinii pneumonia, mouse, 455
  Pseudomonas aeruginosa pulmonary infection, mouse, 1449
  pulmonary response to endotoxin in acute alcohol intoxication, rat, 1441
  pyelonephritis, inflammatory mediators in, rat, 1162
  respiratory syncytial virus vaccination, mouse, 1326
  rotavirus immunity, mouse, S466
  shigellosis treatment, rabbit, 390
  Streptococcus pneumoniae meningitis treatment with rifampin, mouse, 1556
  Streptococcus pyogenes vaccination, mouse, 901
  tetanus toxoid--group B streptococcal vaccine, mouse and rabbit, 142
  Treponema pallidum vertical transmission, guinea pigs, 1206
Anorexia, in Ebola virus infections, S8
Antibody(ies)
  Balamuthia mandrillaris, 1305
  bispecific, in *Candida albicans* phagocytosis and killing, 661
Chlamydia trachomatis major outer membrane protein, response to, mouse model, 180
  cholera, after mucosal vaccination, S493
  Ebola virus (*See* Ebola virus, antibodies to) group A streptococci, rapid chemiluminescence assay for, 1293
  Helicobacter, mouse model, 725
  hepatitis G virus, 1055
  human herpesvirus 8
    in HIV infection, 1590
    small viral capsid antigen, 1016
  human immunodeficiency virus
    in mucosal fluids, S475
    in saliva, S431
  latent membrane protein 1, Epstein-Barr virus, restricted antibody response to, 1108
  neutralizing
    in HIV infection progression, 1365
    parvovirus B19, measurement of, 619
  pneumococcal, assessment with $Fc_\gamma RIIa$, 423
  Pneumocystis carinii, in pneumonia, mouse model, 455
  simian immunodeficiency virus, S480
  Trypanosoma cruzi, detection of, 1226
Antigen(s)
  Chlamydia trachomatis, in epithelial cells, neutrophil chemotaxis to, 954

Chlamydia trachomatis major outer membrane protein, response to, mouse model, 180
Ebola virus, S177
hepatitis B virus, variants, in immunized infants, 259
Schistosoma mansoni, cytokine response to, in acute vs. chronic infection, 1502
Antiretroviral agents, for human immunodeficiency virus infection (*See* HAART (highly active antiretroviral therapy); *specific agents*)
Anuria, in Ebola virus infections, S1, S8
Apoptosis
lymphocytes, in HIV infection, 352, S454
T cells, in tuberculosis, 945
Aqueous humor, cytomegalovirus DNA in, 1249
Ariel Project, for HIV transmission prevention, 319
Arthralgia, in Ebola virus infections, S1, S8, S28
Arthritis
Lyme
inducible nitric oxide synthase and, mouse model, 1572
mouse model, 734
septic, *Staphylococcus aureus*, virulence factors, 291
Arthropods, Ebola virus in, S127, S148
Ascariasis, with schistosomiasis, treatment with albendazole-praziquantel combination, 996
Aspartyl proteinase gene family, as *Candida albicans* virulence factors, rat model, 201
Aspergillus fumigatus, infections, treatment, proinflammatory cytokines, 1038
Asplenia, polysaccharide vaccine response in, 513
Asthenia, in Ebola virus infections, S1
Mosango, S8
Asthma, in viral infections, inflammatory mediator release in, in pediatric patients, 677
Atovaquone-proguanil, for malaria, 1586

B cells, response
to rotavirus, mouse model, S466
to simian immunodeficiency virus, S480
Bacteremia
Enterococcus faecalis, in hemodialysis, 1312
from needleless devices, in home health care, 442
Neisseria meningitidis, neutrophil response in, 1288
Salmonella, in HIV infection, protection with zidovudine, 1552
Staphylococcus aureus, recurrent, pulsed-field gel electrophoresis in, 1157
streptococci, group A, S366
in urinary tract infections, interleukin-6 response in, 172
Bacteria, intracellular, survival mechanisms, S326
Bacterial vaginosis, HIV transmission in, 924
Bactericidal/permeability-increasing protein, recombinant, in *Neisseria meningitidis* infection, 1288
Balamuthia mandrillaris, encephalitis, antibodies to, 1305
Barrett's esophagus, epidemiology, vs. *Helicobacter pylori* decline, 1522
Bartonella, endocarditis, S360
Bats, as virus hosts, S127, S139, S155
BBG2NA respiratory syncytial virus, vaccination, 1326
Beeson, Paul, March Supplement, iv
Bile, TT virus in, 1245
Biofilm, *Staphylococcus epidermidis*, hemagglutination and, 1560
Biopsy, muscle, endothelial cell activation in, in cerebral malaria, 475
Bladder
Ebola virus infection, guinea pig model, S203
Schistosoma haematobium infection, treatment evaluation, 1515
Bleeding, in Ebola virus infections, S1, S15
in pregnancy, S11
primate model, S199
Blindness, in onchocerciasis, epidemiology, Nigeria, 1576
Blood transfusions (*See* Transfusions)
Bone marrow transplantation
cytomegalovirus infections in, cytokines in, 484
human herpesvirus 6 infections in, 311
Bordetella pertussis, genotypic diversity trends, vaccination impact on, The Netherlands, 915
Borrelia burgdorferi, infections
inducible nitric oxide synthase and, mouse model, 1572
interleukin-11 anti-inflammatory action in, mouse model, 734
serodiagnosis
two-test approach, 931
Western blot immunoglobulin M criteria for, 1021
Brain, malaria pathogenesis
mouse model, 217
muscle biopsy and, 475
tumor necrosis factor promoter alleles and, 287
Breast-feeding, HIV transmission in, S405
Burkholderia cepacia, outbreaks, in hospital, 1197
Burkitt's lymphoma, Epstein-Barr virus antibodies in, 1108
Butyrate, for shigellosis, rabbit model, 390

Campylobacter jejuni, ganglioside GM1 mimicry in, 1183
Cancer, gastric, epidemiology, vs. *Helicobacter pylori* decline, 1522
Candida albicans
destruction, enhanced with bispecific antibodies, 661
infections, treatment, proinflammatory cytokines, 1038
pseudohyphal form, neutrophil-mediated activity against, granulocyte colony-stimulating factor effects on, 1301
resistance in, tobramycin, 1190
vaccination, mouse model, 1477
vaginitis, virulence factors, rat model, 201
Capsular polysaccharides, for group B streptococci vaccine, with tetanus toxoid vaccine, 142
Carbocyclic 3-deazaadenosine, for Ebola virus infections, mouse model, S240
Carbohydrate inhibitors, aerosolized, for *Pseudomonas aeruginosa* pneumonia, mouse model, 1449
Carditis, in Lyme disease, mouse model, 734
Carriage
Haemophilus influenzae, in well-vaccinated population, 101
hepatitis B virus, mutations in, 775
hepatitis G virus, HIV infection progression and, 783
Catheter-related infections, central venous, in home health care, 442
CCR5 (*See* Chemokine receptor 5)
CD8+ cell antiviral factor, in HIV inhibition, S485
CD8 suppressor factor, in simian immunodeficiency virus inhibition, S489
CD11b/c molecule, inhibition by endotoxin, in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
CD32 (Fc$_\gamma$RIIa), in pneumococcal antibody assessment, 423
CD64 antigen (FcαRI), antibodies to, in *Candida albicans* phagocytosis and killing, 661
CD89 antigen (FcαRI), antibodies to, in *Candida albicans* phagocytosis and killing, 661
Ceftriaxone, for meningitis, *Streptococcus pneumoniae*, mouse model, 1556
Cellular immune response
in cytomegalovirus infections, after kidney transplantation, 1
to human immunodeficiency virus
anti-HIV inhibitory factor, S485
in gp160 vaccination, 337

in *Pneumocystis carinii* pneumonia, mouse model, 455
to simian immunodeficiency virus, S480
Cerebral malaria
interleukin-6 in, 747
pathogenesis
mouse model, 217
muscle biopsy and, 475
tumor necrosis factor promoter alleles and, 287
Cerebrospinal fluid, leukotrienes inhibition in, in HIV infection, *Toxoplasma gondii* in, 714
Cervix
human papillomavirus infections, in HIV infection, 1405
secretions from, human herpesvirus 8 in, 1533
Chagas' disease, *Trypanosoma cruzi* antibodies detection in, 1226
Chancroid
immune response in, 1283
molecular characterization, 1423
Chemiluminescence assay
for group A streptococci opsonophagocytosis, 1293
for phagocytic oxidative capacity, in HIV infection, 584
Chemokine(s)
from autologous lymph node lymphocyte culture, for HIV infection, 245
coreceptor usage, in HIV infection, as survival time predictor, 859
in HIV vaccination, 558
induction by interleukin-12, chimpanzee model, 646
in respiratory secretions, in virus-induced asthma, in pediatric patients, 677
Chemokine receptor 5 (CCR5)
coreceptor defects, HIV susceptibility and, 538, 548
HIV infection progression and, 825, S384
HIV macrophage infection and, S457
HIV susceptibility and, 1310, S422
Chemotaxis, neutrophil, to *Chlamydia trachomatis*-infected cells, 954
Chimpanzees, Ebola virus infections in
as indicator hosts, S127
outbreaks in nature, S120
pathology, S54
transmission from, S48, S65
Chlamydia trachomatis
in epithelial cells, neutrophil chemotaxis to, 954
infections, current status, S380
major outer membrane protein antibody response, mouse model, 180
Chloroquine, for malaria, 1586
Cholera
pathogenesis, S331
vaccination
mucosal, S493
plus enterotoxigenic *Escherichia coli*, 107
with yellow fever and typhoid vaccination, 522
Chorioamnionitis
in HIV transmission, 319
streptococci group B, 1410
Chorionic villi, human immunodeficiency virus variant selection in, 44
Chronic granulomatous disease
gene therapy for, mouse model, S318
respiratory burst oxidase activation in, S309
Ciprofloxacin
prophylactic, for *Salmonella* bacteremia, in HIV infection, 1552
resistance to, *Neisseria gonorrhoeae*, 729
Clindamycin, for group A streptococcal infections, S366
Clostridium difficile, infections, pathogenesis, S331
Coagulation disorders, in Ebola virus infection, primate model, S199
Coagulation system, interleukin-12 effects on, chimpanzee model, 646
Coccidioides immitis, vaccination, proline-rich antigen for, 518
Cold sores, treatment, famciclovir, 303
Colitis, *Shigella flexneri*, treatment, rabbit model, 390
Collagen, *Staphylococcus aureus* adhesion to, 291
Colon, epithelial cells, HIV interactions with, S444
Colonization (*See also* Carriage)
Helicobacter pylori, changing relationship with humans, 1522
streptococci group B, vaginal, peripartum infections and, 1410
Complement, processing by *Neisseria gonorrhoeae*, 124
Congestive heart failure, exacerbation in respiratory syncytial virus pneumonia, in elderly persons, 25
Conjunctivitis, in Ebola virus infections, S1, S8, S13
Coronary artery disease, cytomegalovirus infections and, 690
Cotrimoxazole, prophylactic, for *Salmonella* bacteremia, in HIV infection, 1552
Coxsackievirus, B3 variant, resistance in, pleconaril, 1537
*cp*45 parainfluenza virus vaccine, efficacy, monkey model, 1345
Cryptococcosis, in HIV infection
epidemiology, 449
surveillance for, 449
Cryptosporidium parvum, cytokines induced by, in immunodeficiency vs. immunocompetency, 967
Cycloguanil, as proguanil metabolite, for malaria, 974
Cyclospora-like organisms, molecular characterization, baboon model, 670
CYP2C19, mutations, in proguanil resistance, 974
Cystic fibrosis
Burkholderia cepacia transmission in, 1197
platelet-activating factor primed phagocyte response in, 151
respiratory microbial flora in, inhaled tobramycin effects on, 1190
Cytochrome B_{558}, as respiratory burst oxidase membrane component, S309
Cytokines (*See also specific cytokines*)
in *Cryptosporidium parvum* infections, in immunodeficiency vs. immunocompetency, 967
in cytomegalovirus infections, 1094
in bone marrow transplantation, 484
in dengue hemorrhagic fever, 755
in Ebola virus infections, S188
in hantavirus pulmonary syndrome, 295
in HIV infection
as markers, 843
pathogenesis, 832
in rectal mucosa, S454
induction
by interleukin-12, chimpanzee model, 646
by vaginal lactobacilli, in HIV defense, 653
inhibition by intracellular bacteria, S326
measurement, S294
in *Plasmodium falciparum* malaria, versus age, 209
in *Pneumocystis carinii* pneumonia, mouse model, 455
proinflammatory
for fungal infections, 1038
induction by peptidoglycan, 1459
in pyelonephritis, rat model, 1162
pyrogenicity, S294
in respiratory secretions, in virus-induced asthma, in pediatric patients, 677
in schistosomiasis, acute vs. chronic, 1502
in simian immunodeficiency virus immunization, S480
in T cells, antigen-specific, after vaccination, 1124
Cytomegalovirus
infections
in bone marrow transplantation, cytokines in, 484

coronary artery disease and, 690
in HIV infection, viral load in, 1101
in kidney transplantation
$\tau\delta$ T lymphocyte expansion after, 1
granzyme B expression in, 693
pathogenesis, 1094
resistance to, ganciclovir, 1352
retinitis
aqueous humor and vitreous viral DNA in, 1249
in HIV infection
ganciclovir resistance in, 1352
treatment, immune recovery vitritis after, 697

Data management, in postdischarge surgical infection identification, 434
Dendritic cells
in HIV replication promotion, S427
response to *Toxoplasma gondii*, 467
Dengue hemorrhagic fever, pathogenesis, 755
Dexamethasone, for hearing loss prevention, in *Streptococcus pneumoniae* meningitis, rabbit model, 264
Dextran, aerosolized, for *Pseudomonas aeruginosa* pneumonia, mouse model, 1449
Diabetes mellitus, foot infection in, colony-stimulating factors for, S342
Dialysis, bacteremia in
Enterococcus faecalis, 1312
Staphylococcus aureus, 1157
Diarrhea
in Ebola virus infections, S1, S8
from enteric pathogens, pathogenesis, S331
Escherichia coli, enterotoxigenic, epidemiology, Egypt, 382
in HIV infection, treatment, S454
severe, in pediatric patients, factors associated with, 1139
Didanosine, resistance to, HIV, 1259
Dideoxyinosine, for human immunodeficiency virus infection, in pediatric patients, 576
Dihydrofolate reductase, mutations, in proguanil resistance, 974
Drug resistance
Alcaligenes xylosoxidans, tobramycin, 1190
Candida albicans, tobramycin, 1190
ciprofloxacin, *Neisseria gonorrhoeae*, 729
coxsackievirus B3 variant, pleconaril, 1537
cytomegalovirus, ganciclovir, 1352
didanosine, HIV, 1259
enterococci, vancomycin, transmission dynamics, 883
ethambutol, *Mycobacterium tuberculosis*, 1025
ganciclovir, cytomegalovirus, 1352
human immunodeficiency virus (*See* Human immunodeficiency virus infection, resistance in)
indinavir, HIV, 1259
isoniazid, *Mycobacterium tuberculosis*, 1025
β-lactams, S353
lamivudine, HIV, 92, 1259
methicillin, S353
Staphylococcus aureus, 883, 1591
multiple, typhoid fever, 1416
Mycobacterium tuberculosis, molecular analysis, 1025
Neisseria gonorrhoeae, ciprofloxacin, 729
nelfinavir, HIV, 1356
penicillin, *Streptococcus pneumoniae*, 892
penicillin-binding proteins, S353
pleconaril, coxsackievirus B3 variant, 1537
pneumococci, S338, S353
proguanil, *Plasmodium*, 974
rifampicin, *Mycobacterium tuberculosis*, 1025
Salmonella typhi, multiple, 1416
Salmonella typhimurium, 1173
saquinavir, HIV, 249, 1259, 1356
staphylococci, S353
Staphylococcus aureus, methicillin, 883, 1591
Streptococcus pneumoniae, penicillin, 892
streptomycin, *Mycobacterium tuberculosis*, 1025
tobramycin, 1190
typhoid fever, multiple, 1416
vancomycin, enterococci
molecular epidemiology, 163
transmission dynamics, 883
zalcitabine, HIV, 249, 1259
zidovudine, HIV, 92, 249, 705, 1259
Duke criteria, for endocarditis, S360
Duodenal ulcers, epidemiology, vs. *Helicobacter pylori* decline, 1522

Ear infections, pneumococcal, rat model, 1145
Ebola virus
in animals, S139
arthropods, S127, S148
bats, S127, S139, S155
primates (*See* Ebola virus infections, in primates)
rodents, S155
vertebrates, S155
antibodies to
in convalescent blood, S18
enzyme-linked immunosorbent assay for, S192
in forest workers, S102
in health care workers, S98
in household contacts, S28
in Kikwit outbreak, S177
in monkey breeding facilities, S115
monoclonal, for treatment, S235
antigens, S177
in arthropods, S127
in bats, S127, S139, S155
in body fluids, S28, S87, S170
health care worker exposure to, S98
Côte d'Ivoire subtype, S48, S54
ecology, S127
detection, S164
discovery, Feb. Supplement, ix
ecology, Feb. Supplement, ix, S127, S139, S148, S155
enzyme-linked immunosorbent assay for, S192
evolutionary relationships, Feb. Supplement, iii
genetic stability, S170
glycoprotein, S164
immunohistochemical assay for, S36
infections (*See* Ebola virus infections)
molecular characterization, S164
mutation, S127
nonpathogenic viruses resembling, S127
persistence, S170
phylogeny, Feb. Supplement, iii
reservoirs for, S127, S139, S155
Reston subtype
ecology, S127
enzyme-linked immunosorbent assay for, S192
in imported primates, S281
molecular characterization, S164
in Philippine monkey breeding facilities, S115
surveillance for, in laboratory primates, S108
virology, S164

subtypes (*See also specific subtypes*)
Sudan subtype, ecology, S127
virology, Feb. Supplement, ix, S164, S177
in Kikwit outbreak (1995), S170
Zaire subtype (*See also* Ebola virus infections, Zaire subtype)
antibodies to, in Kikwit outbreak, S177
ecology, S127
molecular characterization, S164
virology, S164
Ebola virus infections
asymptomatic, in health care workers, S98
clinical features, S1, S8, S18, S76
in convalescence, S1
Côte d'Ivoire subtype, S48
ophthalmic, S13
in pregnancy, S11
primate model, S199
survival and, S24
control, S259, S263, S281, S283
in imported primates, S281
priority actions for, S287
Côte d'Ivoire subtype
clinical features, S48
pathology, S54
diagnosis, S274
immunohistochemical, S36
epidemics
African (1994-1996), Feb. Supplement, ix
priority actions against, S287
epidemiology, Feb. Supplement, ix (*See also* Ebola virus infections, outbreaks)
Gabon (1994-1997), S65
in health care workers, S98
immunoglobulin G antibodies, S102
Kikwit (1995), Feb. Supplement, ix, S76
Mosango, S8
in outbreak control, S259
between outbreaks, S60
Reston subtype, Philippine monkey breeding facilities, S115
yellow fever with, S65
histopathology, primate model, S199
international significance, S283
laboratory diagnosis, S36
in laboratory monkeys, Feb. Supplement, ix
mortality in
determinants, S24
in Gabon outbreaks (1994-1997), S65
immune activation in, S188
Kikwit, S1
Mosango, S8
in pregnancy, S11
in wild chimpanzees, S120
mucormycosis with, S15
natural history, Feb. Supplement, ix, S127, S139, S148
nursing care procedures for, S76, S92, S259, S263, S268, S274
outbreaks
arthropod studies in, S148
in chimpanzees, S120
control, S259, S263
discovery, S259
Kikwit (1995), S1, S76, S259
lessons learned from, S283
Mosango, S8
in nature, S120
surveillance between, S60
virology, S170
pathogenesis, Feb. Supplement, ix
cytokines in, S188
guinea pig model, S203
primate models, S199
pathology, in chimpanzee, S54
in pregnancy, S11
prevention, Feb. Supplement, ix, S274, S283
in primates
chimpanzees, S48, S54, S65, S120, S127
control, S281
laboratory, Feb. Supplement, v
monkeys, Feb. Supplement, ix, S108, S115, S164, S281
outbreaks in nature, S120
pathogenesis, S199
quarantine for, S108
as reservoirs, S127
transmission from, S48, S65
treatment, S218, S224
virology, S164
prophylaxis, hyperimmune serum, S218
protective equipment use in, S76, S92, S259, S263, S268, S274
quarantine for, in laboratory primates, S108
research needs, S283
Reston subtype (*See* Ebola virus, Reston subtype)
risk factors for, S92
in wild chimpanzees, S120
Sudan subtype, S127
surveillance for, S60, S76, S274, S283
in laboratory primates, S108
transmission, S8
among wild chimpanzees, S120
arthropod studies in, S148
from chimpanzees to humans, S48, S65
control, S259, S263, S281
during convalescence, S28
in forest workers versus city workers, S102
genetic stability in, S170
in household contacts, S87
routes, S92
without known exposure, S92
treatment, Feb. Supplement, ix
animal models, S224
blood transfusions, S18
hyperimmune serum, S218
monoclonal antibodies, S235
mouse model, S240, S248
supportive care, S268
yellow fever with, S65
Zaire subtype (*See also* Ebola virus, Zaire subtype)
pathogenesis
guinea pig model, S203
primate model, S199
treatment, mouse model, S240, S248
Economic issues, respiratory syncytial virus pneumonia, in elderly persons, 25
Eimeria, molecular characterization, baboon model, 670
Elastase, in Kawasaki disease pathogenesis, 508
Elderly persons
influenza vaccination in, annually repeated, humoral immune response, 31
nasal secretion collection method for, 1268
Neisseria meningitidis vaccination, 1433

respiratory syncytial virus pneumonia in, disease burden, 25
Electron microscopy, Ebola virus, guinea pig model, S203
Electrophoresis, in recurrent *Staphylococcus aureus* bacteremia, 1157
emm gene, group A streptococci, tissue tropism and, 627
Encephalitis
Balamuthia mandrillaris, antibodies to, 1305
herpes simplex virus, in HIV infection, 714
Toxoplasma gondii, in HIV infection, leukotriene inhibition in, 714
Endocarditis
management, current status of, S360
Staphylococcus aureus, virulence factors, 291
Endometritis, streptococci group B, peripartum, 1410
Endosomes, HIV in, transcytosis, S448
Endothelial cells
activation, in muscle biopsy, in cerebral malaria, 475
Ebola virus infection, guinea pig model, S203
endogenous pyrogen action on, S294
Endotoxemia
interleukin-12 production in, chimpanzee model, 646
leptin in, 1313
macrophage inflammatory proteins in, 136
Endotoxin (*See* Lipopolysaccharide)
Entamoeba histolytica
Gal/GalNac lectin, 460
in T lymphocyte suppression, gerbil model, 1495
Enterococci
endocarditis, S360
resistance in, vancomycin
molecular epidemiology, 163
transmission dynamics, 883
Enterococcus faecalis, bacteremia, in hemodialysis, 1312
Enterocytes, enteropathogenic *Escherichia coli* action on, 269
Enzyme immunoassay, for Lyme disease, 931
Enzyme-linked immunosorbent assay
for Ebola virus, S192
for molluscum contagiosum virus, 701
for *Trypanosoma cruzi* antibodies, 1226
Eosinophils
major basic protein from, in respiratory secretions, in virus-induced asthma, 677
sequestration, in ivermectin treatment, 738
Epidemics
Ebola virus infections, Feb. Supplement, ix
multidrug-resistant typhoid fever, Tajikistan, 1416
Epidemiology
adenovirus infections, in military population, 1530
antibiotic-resistant infections, England and Wales, 883
Bordetella pertussis genotypic diversity, The Netherlands, 915
Burkholderia cepacia infections, in hospital, 1197
cryptococcosis, in HIV infection, 449
Ebola virus infections (*See under* Ebola virus infections)
Escherichia coli infections, enterotoxigenic, in pediatric patients, Egypt, 382
group B streptococci serotypes, in pregnancy, in Japan, 1030
Haemophilus ducreyi, molecular characterization, 1423
Haemophilus influenzae, conjugate vaccination impact on, in Scandinavia, 223
Helicobacter pylori, implications for health and disease, 1522
hemolytic uremic syndrome, sorbitol-fermenting *Escherichia coli* strain in, 1274
hepatitis A, in well water, 37
hepatitis B, mass immunization effects, Taiwan, 367
human herpesvirus 8
in male homosexuals, 237
in women, 234
human immunodeficiency virus infection, S387
combination antiretroviral therapy effects on, 717
Thailand sex workers, 59
molluscum contagiosum virus, Australia, 701
Neisseria gonorrhoeae resistance, Philippines, 729
Neisseria meningitidis infections, disco attendance and, 751
Norwalk-like viruses, common strain with global distribution, 1334
Onchocerca volvulus strains, blinding and nonblinding, Nigeria, 1576
pneumococcal infections, serotype 12F, 414
Salmonella typhi, multidrug-resistant, in Tajikistan, 1416
Streptococcus pneumoniae genetic variations, Canada, 892
TT virus
in blood donors, 1242
Great Britain, 686
typhoid fever, multidrug-resistant, in Tajikistan, 1416
vancomycin resistance in enterococci, in hospital, 163
Epithelial cells
Chlamydia trachomatis-infected, neutrophil chemotaxis to, 954
group A streptococci internalization in, fibronectin-binding protein, 1049
HIV interactions with, S436, S441, S444
transcytosis in, S448
Epstein-Barr virus
infections
chronic active, viral loads in, 1012
in infants of HIV-infected mothers, 1395
latent membrane protein 1
polymorphisms in HIV infection, 240
restricted antibody response to, 1108
sequence variation, 763
Errata
antiretroviral therapy (1999;179:527), 1315
experimental pneumococcal meningitis (1999;178:264), 753
granulocyte colony-stimulating factor in *Mycobacterium avium* complex infections (1998;178:1530), 1315
resistance to antiretroviral drugs (1998;178:1497), 1316
varicella-zoster virus immunity (1998;178:S104), 753
viral hepatitis symposium (1999:179:44), 1053
ESAT-6 antigen, *Mycobacterium tuberculosis*, T cell response to, 637
Escherichia coli
enteroaggregative, infections, S331
enteropathogenic
bundle-forming pilus, 269
infections
pathogenic, S331
in pediatric patients, 1139
virulence factors, 269
enterotoxigenic
infections, epidemiology, in pediatric patients, Egypt, 382
vaccination, plus cholera toxin B subunit, 107
non-O157:H7 pathogenic Shiga toxin--producing, virulence factors, 115
O:113, endotoxin, inflammatory effects of new clinical lot, 1278
O157:H7, in hemolytic uremic syndrome outbreak, 1274
pyelonephritis, inflammatory mediators in, rat model, 1162
Shiga toxin-producing, pathogenetic effects, 503
Esophageal disease, epidemiology, vs. *Helicobacter pylori* decline, 1522
Ethambutol, resistance to, *Mycobacterium tuberculosis*, 1025
Ethanol, acute intoxication, pulmonary endotoxin response in, granulocyte colony-stimulating factor effects on, rat model, 1441
Exotoxin(s), group A streptococci, tissue tropism and, 627

Extracellular signal-regulated mitogen-activated protein kinase, in nitric oxide synthase and tumor necrosis factor induction, with lipopolysaccharide-interferon-ô stimulation, 939
Eye infections
cytomegalovirus, aqueous humor and vitreous viral DNA in, 1249
Ebola virus, S13
herpes simplex virus type 1, interleukins in, 1086

F1 protein (fibronectin-binding protein), in group A streptococci internalization in epithelial cells, 1049
Famciclovir, for herpes simplex virus infections, labial, 303
Fasciitis, necrotizing, group A streptococci, S366
Fatty acids, short-chain, for shigellosis, rabbit model, 390
FcαRI antibodies, in *Candida albicans* phagocytosis and killing, 661
FcγRI antibodies, in *Candida albicans* phagocytosis and killing, 661
Fc,RIIa (CD32), in pneumococcal antibody assessment, 423
Ferritin, in chronic liver disease, *Vibrio vulnificus* survival and, 275
Fetus, maternal malaria effects on, 1579
Fever
in Ebola virus infections, S1, S8
hemorrhagic, Ebola virus (*See* Ebola virus infections)
induction, cytokines in, S294
in urinary tract infections, interleukin-6 response in, 172
Fibrin deposition, in Ebola virus infection, guinea pig model, S203
Fibrinolysis, interleukin-12 effects on, chimpanzee model, 646
Fibroblasts
cytomegalovirus infections, interleukin-6 production in, 1094
Ebola virus infections, guinea pig model, S203
Fibronectin-binding protein
in group A streptococci internalization in epithelial cells, 1049
in *Streptococcus pyogenes* vaccine, mouse model, 901
Filoviridae, Feb. Supplement, ix
Flesh-eating bacterium (highly-invasive group A streptococci), S366
Foreign bodies, *Staphylococcus aureus* bacteremia related to, 1157
c-Fos protein, in HIV transactivation, in colon epithelial cells, S444
Foscarnet, for cytomegalovirus infections, in HIV infection, 1101
Free radicals, oxygen (*See* Oxygen free radicals)
Fulminant hepatitis, hepatitis C virus, transmission, chimpanzee model, 1007
Fungal infections (*See also specific infections and organisms*)
colony-stimulating factors for, S342
treatment, proinflammatory cytokines, 1038
Fusarium solani, infections, treatment, proinflammatory cytokines, 1038

G protein, in cytomegalovirus infection pathogenesis, 1094
Gal/GalNac lectin, *Entamoeba histolytica*, 460
Ganciclovir
for cytomegalovirus infections, in HIV infection, 1101
resistance in, cytomegalovirus, 1352
Ganglioside GM1 mimicry, in *Campylobacter jejuni*, 1183
Gardnerella vaginalis, in HIV activation, 924
Gastric cancer, epidemiology, vs. *Helicobacter pylori* decline, 1522
Gastritis, epidemiology, vs. *Helicobacter pylori* decline, 1522
Gastroenteritis, Norwalk-like viruses, common strain with global distribution, 1334
Gastroesophageal reflux, epidemiology, vs. *Helicobacter pylori* decline, 1522
Gastrointestinal tract
Ebola virus infection, guinea pig model, S203
mucosa of, HIV transmission through, S392, S444
disease characterization in, S454
GB virus C (hepatitis G virus), infections
coinfection with hepatitis C, 1055
HIV infection progression and, 783
TT virus and, 1070
Gene therapy, for chronic granulomatous disease, mouse model, S318
Genital herpes
antibodies to, sexual risk behavior and, 16
major histocompatibility complex and, 1077
Genital tract
Chlamydia trachomatis infections
antigen persistence in, 954
current status, S380
Ebola virus in, S170
Haemophilus ducreyi infections, immune response to, 1283
herpes simplex virus type 2 infections, sexual behavior patterns and, 16
HIV RNA in, vs. blood levels, 871
human herpesvirus 8 infections, 234
human papillomavirus infections, treatment, vaccine in, 612
mucosal immunity, S470
ulcers, *Haemophilus ducreyi*, 1423
vaccination in, cholera, S493
Geohelminth infections, with schistosomiasis, treatment with albendazole-praziquantel combination, 996
Glycoproteins
Ebola virus, S164
on epithelial cells, HIV transmission and, S441
functional blockade, by hookworm platelet inhibitor, 1235
in otitis media, rat model, 1145
Pneumocystis carinii, characterization, rat model, 192
Gonococci (*See Neisseria gonorrhoeae*)
gp120 antigen, in HIV vaccine, 558, 817
gp160 antigen, in HIV vaccine, 337, 817
Gram-positive organisms, peptidoglycan, in proinflammatory cytokine induction, 1459
Granulocyte colony-stimulating factor
for *Candida albicans* infections, 661, 1301
for fungal infections, 1038
for pulmonary endotoxin response modulation, in acute alcohol intoxication, rat model, 1441
Granulocyte-macrophage colony-stimulating factor
for fungal infections, 1038
in nonneutropenic persons, S342
Granulomatous amoebic encephalitis, *Balamuthia mandrillaris*, 1305
Granzyme B, in cytomegalovirus infections, after kidney transplantation, 693
Guillain-Barre syndrome, in *Campylobacter jejuni* infections, ganglioside GM1 mimicry and, 1183

HAART (highly active antiretroviral therapy), for HIV infection, S392
failure, 790
immune recovery vitritis after, 697
tumor necrosis factor activation n, 74
Haemophilus ducreyi
infections, immune response to, 1283
molecular characterization, 1423
Haemophilus influenzae
invasive, reemergence in well-vaccinated population, 101
vaccination
in asplenia, 513
conjugate, impact in Scandinavia, 223
disease re-emergence and, 101
Hansen's disease (leprosy)
immune response in, 1034
susceptibility to, vitamin D receptor genotype and, 187
Hantavirus pulmonary syndrome, pathogenesis, cytokine-producing cells in, 295

HBY 097, for HIV infection, 709
Headache, in Ebola virus infections, S1, S8
Health care workers, Ebola virus infections in, S98, S263, S268
Hearing loss, in *Streptococcus pneumoniae* meningitis, rabbit model, 264
Heat-shock protein 60, self, peptide from, in pneumococcal vaccine, 403
Helicobacter, antibody response, mouse model, 725
Helicobacter pylori
changing relationships with humans, 1522
transmission, parent-child, 398
Helminth infections, with schistosomiasis, treatment with albendazole-praziquantel combination, 996
Hemagglutination, *Staphylococcus epidermidis*, biofilm formation and, 1560
Hemodialysis, bacteremia in
Enterococcus faecalis, 1312
Staphylococcus aureus, 1157
Hemoglobin E trait, *Plasmodium falciparum* malaria with, 283
Hemolytic-uremic syndrome
outbreak, sorbitol-fermenting *Escherichia coli* strain in, 1274
pathogenesis, 503
Hemophilia
HIV infection in, hepatitis C with, 1254
multiple transfusions in, hepatitis C virus genotypic changes in, 1062
Hemorrhage (*See* Bleeding)
Hemorrhagic fever
dengue, pathogenesis, 755
Ebola virus (*See* Ebola virus infections)
Hepatitis
non-A--G, TT virus in, 1245
posttransfusion, TT virus and, 686
Hepatitis A virus, epidemiology, in well water, 37
Hepatitis B virus
antibodies to, protective level, 489
infections
persistence in African Americans, HLA alleles and, 1004
tuberculosis with, vitamin D receptor gene variations and, 721
mutations, in carriers, liver damage and, 775
seroepidemiology, mass immunization effects, Taiwan, 367
surface antigen variants, in immunized infants, 259
vaccination
in high-risk infants, 1319
non "a" determinant, in immunized infants, 259
protective antibody level, 489
seroepidemiology after, Taiwan, 367
Hepatitis C virus
genotypic changes in, in multitransfused hemophiliacs, 1062
infections
in HIV infection, in hemophilia, 1254
human leukocyte antigens and, 1309
transmission, chimpanzee model, 1007
viremia dynamics, 291
Hepatitis G virus (GB virus C), infections
hepatitis C coinfection with, 1055
HIV infection progression and, 783
TT virus and, 1070
Hepatoma, *Vibrio vulnificus* survival in, 275
Herpes simplex virus
encephalitis, in HIV infection, 714
infections, labial, treatment, famciclovir, 303
type 1, ocular, interleukins in, mouse model, 1086
type 2
antibodies, sexual risk behavior and, 16
infections, major histocompatibility complex and, 1077
sexual risk behavior and, 16
Herpes zoster, persistent pain in, risk categories, 9
Heteroduplex mobility assay analysis, for human immunodeficiency virus, in placenta, 44
Highly active antiretroviral therapy (*See* HAART (highly active antiretroviral therapy))
HIV (*See* Human immunodeficiency virus)
Hodgkin's disease, Epstein-Barr virus antibodies in, 1108
Home health care, bacteremia in, from needleless devices, 442
Hook, Edward W., Jr., tribute to, 1317
Hookworms
infections, with schistosomiasis, treatment with albendazole-praziquantel combination, 996
platelet inhibitor of, 1235
Host defense
Mycobacterium avium complex, S461
vaginal, against HIV, 653
Human herpesvirus 6
in cord blood cells, 1046
infections, in bone marrow transplantation, 311
Human herpesvirus 8
antibodies to
in blood donors, 1590
in HIV infection, 1590
in cervicovaginal secretions, 1533
in HIV infection, 1533
seroepidemiology
in male homosexuals, 237
in women, 234
small viral capsid antigen, major antibody-reactive epitope of, 1016
in women, 234
Human immunodeficiency virus (type 1 and unspecified)
activation by *Gardnerella vaginalis*, 924
antibodies to, in mucosal fluids, S475
dNA, in nonprogressors, longitudinal quantification, 1541
downstream regulatory elements, protein kinase activation and, S444
host defense against, vaginal lactobacilli, 653
immune response to
in highly exposed sex workers, 59
vaginal lactobacilli in, 653
inhibitory factor, S485
long terminal repeat, protein kinase activation and, S444
mutations, 705
placental transport, 44
replication
in dendritic cells, S427
after early antiretroviral drug treatment, 527
inhibition by CD8+ cell antiviral factor, S485
interleukin-16 effects on, 83
opportunistic pathogens effects on, S457
RNA
in antiretroviral therapy evaluation, 361
in blood vs. female genital tract, 871
human papillomavirus infection and, 1405
maternal levels vs. infant transmission risk and, 1382, 1388
in nonprogressors, longitudinal quantification, 1541
in rectal mucosa, S454
shedding, transmission and, S401
subtypes, progression and, 68
transcription, protein kinases in, S444
Human immunodeficiency virus infection (type 1 and unspecified)
advanced, treatment, 329
animal models (*See* Simian immunodeficiency virus infection)
asymptomatic (nonprogressive)

neutralization escape variants in, 1264
neutralizing antibodies and, 1365
viral DNA and RNA longitudinal quantification in, 1541
in bacterial vaginosis, 924
cryptococcosis in, surveillance for, 449
cryptosporidiosis in, cytokine profile in, 967
cytokines in, as markers, 843
cytomegalovirus infections in
retinitis, ganciclovir resistance in, 1352
viral load in, 1101
diarrhea in, treatment, S454
encephalitis in, *Toxoplasma gondii*, leukotriene inhibition in, 714
epidemiology, S387
combination antiretroviral therapy effects on, 717
Thailand sex workers, 59
Epstein-Barr virus infections in, natural history, in pediatric patients, 1395
Epstein-Barr virus latent membrane protein 1 polymorphisms in, 240
hepatitis C in, in hemophilia, 1254
hepatitis G in, disease progression and, 783
human herpesvirus 8 in
antibodies to, 1590
detection, 1533
human papillomavirus infection in, 1405
human T cell leukemia/lymphoma virus coinfection with, macaque model, 600
of intestinal epithelial cells, S444
maternal, infant Epstein-Barr virus infection natural history and, 1395
molluscum contagiosum in, 701
monitoring, interleukin-16 level sin, 83
mortality in, combination antiretroviral therapy effects on, 717
mucosal immunity in, S392, S397, S475
Mycobacterium avium complex infection in, pathophysiology, S461
natural history, determinants, S384
in neutralization-escape variants, progression, 1264
nonprogression
neutralization escape variants in, 1264
neutralizing antibodies and, 1365
viral DNA and RNA longitudinal quantification in, 1541
pathogenesis
cofactors for macrophage entry, S422, S457
cytokines in, 832
dendritic cells in, S427
intestinal, S454
mucosal events in, S436
mucosal immunity and, S392, S397
opportunistic pathogens in, S457
tumor necrosis factor in, 74
in pediatric patients (*See* Pediatric patients, human immunodeficiency virus infection in) risk factors for, 52
phagocyte oxidative capacity impairment in, in pediatric patients, 584
prevention, in breast-feeding, S405
primary, treatment, 1548
prognosis
determinants, S384
with syncytium-inducing phenotype, 254
progression
chemokine receptor mutations and, 825
in children, transmission timing and, 52
cytotoxic T lymphocytes and, 538, 548
determinants, S384
vs. Epstein-Barr virus shedding, in pediatric patients, 1395
in hepatitis G coinfection, 783
in human T cell leukemia/lymphoma virus coinfection, macaque model, 600
inhibition by CD8+ cell antiviral factor, S485
in neutralization-escape variants, 1264
neutralizing antibodies and, 1365
prediction, 859
with primary zidovudine treatment, 1548
subtypes and, 68
resistance in, 538, 548
in Brazil, 1259
in highly exposed sex workers, 59
indinavir, 1259
lamivudine, 92, 1259
nelfinavir, 1356
saquinavir, 1356
zalcitabine, 249, 1259
zidovudine, 92, 249, 705, 1259
retinitis in, cytomegalovirus, ganciclovir resistance in, 1352
risk factors, transmission timing and, 52
subtype E, perinatal transmission, 590
susceptibility to
CCR5 chemoreceptor and, 1310, S422
cytotoxic T lymphocyte activity and, 538, 548
opportunistic pathogens and, S457, S475
syncytium-inducing phenotype, prognosis, 254
T cells in
activation in, as survival time predictor, 859
activation-associated necrosis, 352
interleukin-12 enhancement, 493
Toxoplasma gondii encephalitis in, leukotriene inhibition in, 714
transmission, S387
in bacterial vaginosis, 924
in breast-feeding, S405
factors affecting, S401
across gastrointestinal mucosa, S392
in genital-oral contact, primate model, S408
intestinal mucosa, S436
in Kenya, S401
M cells and, S441
mucosal (*See* Mucosa, HIV transmission through)
mucosal immunity and, S392, S397, S475
oral
mucosal antiviral factors as barriers to, S431
primate model, S408
perinatal
maternal immunologic characteristics and, 1388
maternal virus load and, 590, 1388
mucosal immunity and, S392
placental transport and, 44
prevention, 319, 567
risk factors for, 52, 319
subtype E, 590
zidovudine resistance and, 705
Zimbabwe, 1382
protection against, T-lymphocytes in, 538, 548
rectal
to chimpanzees, S418
M cells and, S441
risk factors for, 590
timing, disease progression and, 52
transcytosis in, S448
vaginal, primate model, S413
treatment (*See also* HAART (highly active antiretroviral therapy))
abacavir, in four-drug combination salvage therapy, 1375
amprenavir, 808
combination, 527, 717, 808, 1116

drug resistance in, 1356
nevirapine-indinavir, 1116
nevirapine-indinavir with new nucleoside reverse transcriptase inhibitors, 1356
in pediatric patients, 576
as salvage therapy, 1375
viral dynamics in, 799
drug resistance mutations in, 249
in early stages, 527, 849
failure, four-drug salvage regimen for, 1375
HBY 097, 709
immune recovery vitritis after, 697
immunotherapy with autologous lymph node lymphocytes, 245
indinavir (*See* Indinavir, for HIV infection)
interleukin-2 injection in, 849
in intestinal disease, S454
lamivudine (*See* Lamivudine, for HIV infection)
macrophage inflammatory proteins, 245
monitoring, with HIV RNA measurement, 361
nelfinavir
in four-drug combination salvage therapy, 1375
resistance in, 1356
nevirapine (*See* Nevirapine, for HIV infection)
in pediatric patients, 576
primary, 1548
protection against *Salmonella* bacteremia recurrence, 1552
resistant, 1259
reverse transcriptase mutations during, 92
ritonavir (*See* Ritonavir, for HIV infection)
RNA measurement in, 361
T cell response in, 329, 345
triple therapy, 329
tumor necrosis factor activation in, 74
viral dynamics in, 799
zidovudine (*See* Zidovudine, for HIV infection)
tuberculosis in
detection, 1293
drug resistant, 1025
vaccination, 817
with gp120, 558
with gp160, 337
intracellular antigen-specific cytokine development in, 1124
mucosal, S392
viral load in
in blood vs. female genital tract, 871
in human T cell leukemia/lymphoma virus coinfection, macaque model, 600
perinatal transmission and, 590
vs. prognosis, S384
as survival time predictor, 859
Human leukocyte antigens
hepatitis B persistence and, in African Americans, 1004
hepatitis C and, 1309
herpes simplex type 2 infection clinical spectrum and, 1077
HIV resistance and, 59
laryngeal papillomatosis and, 682
Plasmodium falciparum malaria and, 1042
tuberculosis and, 1051
Human papillomavirus
infections, in HIV infection, 1405
vaccines, 612
Human parainfluenza virus, vaccination, monkey model, 1345
Human T cell leukemia/lymphoma virus type I
HIV coinfection with, macaque model, 600
in salivary glands, 497
Humoral immune response (*See also* Antibody(ies))
to Epstein-Barr virus latent membrane protein 1, 1108
to human immunodeficiency virus
in highly exposed sex workers, 59
mucosal, S475
in influenza vaccination, annually repeated, 31
to simian immunodeficiency virus, S480
Hyperimmune immunoglobulin
for Ebola virus infections, S218
for HIV infection, in perinatal transmission prevention, 567
Hyperlacrimation, in Ebola virus infections, S13

Ibuprofen, in experimental endotoxemia, macrophage inflammatory proteins and, 136
ica gene product, *Staphylococcus epidermidis*, in biofilm formation, 1560
Imidazoloquinolones, for leishmaniasis, mouse model, 1485
Imiquimod, for leishmaniasis, mouse model, 1485
Immune globulin (*See also* Hyperimmune immunoglobulin)
for Ebola virus infections, S218
animal models, S224
Immune recovery vitritis, in cytomegalovirus retinitis, in HIV infection, 697
Immune response (*See also* Cellular immune response; Humoral immune response)
to *Candida albicans*, facilitation with bispecific antibodies, 661
to endotoxin, in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
to enterotoxigenic *Escherichia coli* plus cholera toxin subunit B vaccine, 107
to Epstein-Barr virus latent membrane protein 1, 1108
to *Haemophilus ducreyi*, 1283
to hepatitis B virus, in African Americans, 1004
to herpes simplex virus type 1, in eye, mouse model, 1086
to herpes simplex virus type 2, 1077
to human immunodeficiency virus
after early antiretroviral drug treatment, 527
in highly exposed sex workers, 59
T lymphocytes in, 538, 548
vaginal lactobacilli in, 653
to human immunodeficiency virus vaccine, 558
to intracellular bacteria, S326
mucosal (*See* Mucosal immunity)
to *Mycobacterium leprae* recombinant proteins, 1034
to parvovirus B19, quantitative analysis, 619
to *Plasmodium falciparum*, 989
reactive oxygen intermediates in, 1583
to pneumococcal vaccination, in otitis media, 1152
to rotavirus, mouse model, S466
to vaccination, antigen-specific cytokine development, 1124
Immunization (*See* Vaccination)
Immunodeficiency (*See also* Human immunodeficiency virus infection; Transplantation)
fungal infections in, treatment, proinflammatory cytokines, 1038
Immunoglobulin(s)
in convalescent blood, for Ebola virus infections, S18
ebola virus, in Kikwit outbreak, S177
in genital tract, S470
in HIV transcytosis inhibition, at epithelial barrier, S448
hyperimmune, for human immunodeficiency virus infection, in perinatal transmission prevention, 567
in mucosal fluids, HIV-specific, S475
Immunoglobulin A

in HIV resistance, 59
virus-specific, measurement, nasal secretion collection method for, 1268
Immunoglobulin M, criteria for, in Western blot for Lyme disease, 1021
Immunohistochemical assay
for Ebola virus, S36
guinea pig model, S203
for Rocky Mountain spotted fever confirmation, 1469
Immunomodulators, for leishmaniasis, mouse model, 1485
Immunotherapy, for HIV infection, autologous lymph node lymphocytes in, 245
Impetigo, group A streptococci, genetic studies, 627
In situ hybridization, Ebola virus, guinea pig model, S203
Indinavir, for HIV infection
failure, 1375
in HAART regime, failure, 790
nevirapine and new nucleoside reverse transcriptase inhibitors with, 1356
nevirapine with, 1124
resistance to, 1259
T cell response in, 345
in triple therapy, 329
Indirect immunofluorescence assay
for human herpesvirus 8 antibodies, 234, 237
for Rocky Mountain spotted fever confirmation, 1469
Infection control, in home health care, with needleless devices, 442
Infectious mononucleosis, chronic active, viral loads in, 1012
Influenza virus, vaccination
A/Hong Kong, ferret and chicken models, 1132
annually repeated, humoral immune response, 31
Integrins, functional blockade, by hookworm platelet inhibitor, 1235
Intercellular adhesins, *Staphylococcus epidermidis*, in biofilm formation, 1560
Interferon(s)
in hantavirus pulmonary syndrome, 295
measurement, S294
pyrogenicity, S294
Interferon-α, in Ebola virus infections, S188
Interferon-α2b, for Ebola virus infections, animal models, S224
Interferon-τ
in *Cryptosporidium parvum* infections, in immunodeficiency vs. immunocompetency, 967
deficiency, in tuberculosis, 945
in dengue hemorrhagic fever, 755
in Ebola virus infections, S188
for fungal infections, 1038
in HIV infection, as marker, 843
induction by interleukin-12, chimpanzee model, 646
in leprosy, 1034
with lipopolysaccharide, nitric oxide synthase and tumor necrosis factor induction by, pathways for, 939
in malaria resistance, placental, 1218
in *Plasmodium falciparum* malaria, versus age, 209
Plasmodium falciparum reinfection resistance and, 980
in *Pneumocystis carinii* pneumonia, mouse model, 455
release, whole blood assay for, vs. tuberculin skin test, 1293
in schistosomiasis, acute vs. chronic, 1502
in simian immunodeficiency virus immunization, S480
in T cells, antigen-specific, after vaccination, 1124
Interleukin(s)
in *Cryptosporidium parvum* infections, in immunodeficiency vs. immunocompetency, 967
in cytomegalovirus infections, in bone marrow transplantation, 484
in hantavirus pulmonary syndrome, 295
in herpes simplex virus type 1 infections, ocular, mouse model, 1086
in HIV infection, in rectal mucosa, S454
induction by interleukin-12, chimpanzee model, 646
in leishmaniasis, mouse model, S305
in malaria resistance, placental, 1218
measurement, S294
in *Plasmodium falciparum* malaria, versus age, 209
in *Pneumocystis carinii* pneumonia, mouse model, 455
in pyelonephritis, rat model, 1162
pyrogenicity, S294
in simian immunodeficiency virus immunization, S480
Interleukin-1, induction by peptidoglycan, 1459
Interleukin-1β, induction by vaginal lactobacilli, in HIV defense, 653
Interleukin-2
deficiency, in tuberculosis, 945
in Ebola virus infections, S188
for HIV infection, 849
inhibition, by *Entamoeba histolytica*, gerbil model, 1495
receptor for
in dengue hemorrhagic fever, 755
in HIV infection, as marker, 843
Interleukin-4
soluble receptor for, in visceral leishmaniasis, 743
in T cells, antigen-specific, after vaccination, 1124
Interleukin-5
ivermectin adverse reaction, 738
in respiratory secretions, in virus-induced asthma, in pediatric patients, 677
Interleukin-6
in cytomegalovirus infection pathogenesis, 1094
in HIV infection pathogenesis, 832
induction by peptidoglycan, 1459
in malaria, 747
in urinary tract infections, 172
Interleukin-10
in Ebola virus infections, S188
ratio with tumor necrosis factor-a, in malaria, anemia and, 279
in schistosomiasis, acute vs. chronic, 1502
Interleukin-11, anti-inflammatory action, in Lyme disease, mouse model, 734
Interleukin-12
from dendritic cells, in *Toxoplasma gondii* response, 467
in inflammation induction, chimpanzee model, 646
in T cell response enhancement, in HIV infection, 493
Interleukin-16, in human immunodeficiency virus replication inhibition, 83
Interplanetary Society Meeting (1997), March Supplement
Intestinal bacteria, pathogenic effects, S331
Intestine, mucosa, HIV interactions with, S436, S441, S444
antiretroviral therapy effects on, S454
Intraamniotic infections, streptococci group B, 1410
Intracellular bacteria, survival mechanisms, S326
Intrauterine growth retardation, in maternal malaria, 1579
Isoniazid, resistance to, *Mycobacterium tuberculosis*, 1025
Ivermectin, for onchocerciasis, adverse reactions to, 738

JunD protein, in HIV transactivation, in colon epithelial cells, S444
Jurkat T cells, activation, vaginal lactobacilli in, in HIV defense, 653

Kaposi's sarcoma, causative organism (*See* Human herpesvirus 8)
Kass Lecture, *Helicobacter pylori* changing relationship with humans, 1522
Kawasaki disease, pathogenesis, lipopolysacharide-bound neutrophils in, 508

Ketorolac, for hearing loss prevention, in *Streptococcus pneumoniae* meningitis, rabbit model, 264
Kidney
  Ebola virus infection, guinea pig model, S203
  failure
    dialysis-related bacteremia in
      Enterococcus faecalis, 1312
      Staphylococcus aureus, 1157
    in malaria, 747
  infections, inflammatory mediators in, rat model, 1162
  transplantation, cytomegalovirus infections in
    $\tau\delta$ T lymphocyte expansion after, 1
    granzyme B expression in, 693

LACK protein, in leishmaniasis, mouse model, S305
Lacrimation, in Ebola virus infections, S13
β-Lactamase, *Salmonella typhimurium*, 1173
β-Lactams, resistance to, S353
Lactobacilli, vaginal, as HIV defense, 653
Lamina propria, HIV interactions with, S436
Lamivudine, for HIV infection
  in combination therapy, 808
    viral dynamics in, 799
  in early stages, 527
  resistance to, 1259
  reverse transcriptase mutations and, 92
  T cell response in, 345
  in triple therapy, 329
Langerhans cells, genital tract, simian immunodeficiency virus infection, S413
Larynx, papillomatosis, human leukocyte antigens and, 682
Latent membrane protein 1, Epstein-Barr virus
  polymorphisms in HIV infection, 240
  restricted antibody response to, 1108
  sequence variation, 763
Lectin, Gal/GalNac, *Entamoeba histolytica*, 460
Leishmaniasis
  susceptibility to, mouse model, S305
  treatment, immunomodulators for, mouse model, 1485
  visceral, soluble interleukin-4 receptor in, 743
Leprosy
  immune response in, 1034
  susceptibility to, vitamin D receptor genotype and, 187
Leptin
  in endotoxemia, 1313
  Salmonella abortus equi endotoxin effects on, 1047
Leukocyte(s), cytomegalovirus pp150 transcript in, in HIV infection, 1101
Leukocyte oxidase deficiency, chronic granulomatous disease in, gene therapy for, mouse model, S318
Leukocyte receptors, in pneumococcal antibody assessment, 423
Leukocytosis, induction by interleukin-12, chimpanzee model, 646
Leukotrienes
  inhibition, in HIV infection, *Toxoplasma gondii* in, 714
  in otitis media, rat model, 1145
Line probe assay, for hepatitis C virus, in multiple transfusions, 1062
Lip, herpes simplex virus infections, treatment, famciclovir, 303
Lipopolysaccharide (endotoxin)
  Escherichia coli O:113, inflammatory effects of new clinical lot, 1278
  generation, in *Chlamydia trachomatis*-infected cells, neutrophil chemotaxis and, 954
  in HIV infection pathogenesis, 832
  with interferon-ô, nitric oxide synthase and tumor necrosis factor induction by, pathways for, 939
  in Kawasaki disease pathogenesis, 508
  pulmonary response to, in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
  Salmonella abortus equi, leptin plasma levels and, 1047
Lipoxygenase
  inhibition, in HIV infection, *Toxoplasma gondii* in, 714
  in otitis media, rat model, 1145
Liver (*See also* Hepatitis)
  amebic abscess, T lymphocyte suppression in, gerbil model, 1495
  chronic disease, *Vibrio vulnificus* survival in, 275
  damage in hepatitis B, vs. mutations, 775
  Ebola virus infection
    guinea pig model, S203
    pathology, S54
  transplantation, fulminant hepatitis C after, 1007
Lung
  Ebola virus infection, guinea pig model, S203
  fibroblasts, cytomegalovirus infections, interleukin-6 production in, 1094
  infections (*See* Pneumonia)
  response to endotoxin, in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
Lyme disease
  inducible nitric oxide synthase and, mouse model, 1572
  interleukin-11 anti-inflammatory action in, mouse model, 734
  serodiagnosis
    two-test approach, 931
    Western blot immunoglobulin M criteria for, 1021
Lymph nodes
  Ebola virus in, guinea pig model, S203
  lymphocytes from, for human immunodeficiency virus infection, 245
  as vaccination target, for simian immunodeficiency virus, S489
Lymphocyte(s) (*See also* B cells; T cells)
  Epstein-Barr virus in, in persistent infections, 1012
Lymphocyte outgrowth assay, CD4, in antiretroviral therapy evaluation, 345
Lymphocyte proliferation assay, in HIV infection, interleukin-12 Effects on, 493
Lymphocyte-activating factor, S294
Lymphoma
  Epstein-Barr virus antibodies in, 1108
  in HIV infection, Epstein-Barr virus latent membrane protein 1 polymorphisms in, 240

M cells, in mucosal immunity, HIV infection and, S392, S441
Macrophage(s)
  activation, vaginal lactobacilli in, in HIV defense, 653
  bacteria within, survival mechanisms, S326
  colony-stimulating factor effects on, S342
  cytokine production in, in HIV infection pathogenesis, 832
  Ebola virus infections
    guinea pig model, S203
    primate model, S199
  HIV entry into, cofactors for, S422, S457
  leishmanicidal activity in, immunomodulator stimulation of, mouse model, 1485
  lipopolysaccharide-interferon-ô stimulation, nitric oxide synthase and tumor necrosis factor accumulation in, 939
  Mycobacterium tuberculosis replication in, 1213
Macrophage inflammatory protein(s)
  in endotoxemia, 136
  in HIV infection, 245
  in HIV vaccination, 558
  induction by interleukin-12, chimpanzee model, 646

Macrophage inflammatory protein-2
inhibition by endotoxin, in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
in simian immunodeficiency virus inhibition, S489
Macrophage-inhibitory protein-1α, in respiratory secretions, in virus-induced asthma, in pediatric patients, 677
Major basic protein, in respiratory secretions, in virus-induced asthma, in pediatric patients, 677
Major histocompatibility complex (*See* Human leukocyte antigens)
Major surface glycoprotein, *Pneumocystis carinii*, characterization, rat model, 192
Malaria
cerebral, interleukin-6 in, 747
interleukin-6 in, 747
placental, immunity to, 1218
Plasmodium berghei, pathogenesis, mouse model, 217
Plasmodium falciparum
anemia in
interleukin-10/tumor necrosis factor-α ratio in, 279
tumor necrosis factor promoter alleles in, 287
complexity, immunity and, 989
cytokine-producing T cells in, versus age, 209
with hemoglobin E trait, 283
human leukocyte antigen alleles in, 1042
in pregnancy, fetal effects, 1579
reactive oxygen intermediates in, 1583
resistance to reinfection, interferon-ô and, 980
severity, muscle biopsy and, 475
treatment, 974, 1586
Plasmodium vivax, proguanil for, 974
resistance in, proguanil, 974
Mannan extract-protein conjugate, *Candida albicans*, for vaccination, mouse model, 1477
Marburg virus, Feb. Supplement, ix
ecology, S127
reservoirs for, S127
Medical records, in postdischarge surgical infection identification, 434
Meningitis, *Streptococcus pneumoniae*
hearing loss in, rabbit model, 264
treatment with rifampin, mouse model, 1556
Meningococci
infections
epidemiology, disco attendance and, 751
neutrophil response in, 1288
serogroup C conjugate, vaccination, 1564
Meningoencephalitis, West Nile virus, risk factors for, in Romania, 230
Merozoites, *Plasmodium falciparum*, surface antigens, 1042
Methicillin, resistance to
staphylococci, S353
Staphylococcus aureus, 1591
transmission dynamics, 883
β_2-Microglobulin, in HIV infection, as marker, 843
Milk, breast, HIV transmission in, S405
Mimicry, ganglioside GM1, in *Campylobacter jejuni*, 1183
Mitogen-activated protein kinase, extracellular signal-regulated, in nitric oxide synthase and tumor necrosis factor induction, with lipopolysaccharide-interferon-ô stimulation, 939
Molluscum contagiosum virus, epidemiology, Australia, 701
Monoclonal antibodies, for Ebola virus infections, S235
Monocyte(s)
Ebola virus infection, primate model, S199
proinflammatory cytokine secretion from, induction by peptidoglycan, 1459
response to *Schistosoma mansoni* antigens, in acute vs. chronic infection, 1502
Monocyte chemoattractant protein-1, induction by interleukin-12, chimpanzee model, 646
Mortality
Ebola virus infections (*See under* Ebola virus infections)
human immunodeficiency virus infection, combination treatment effects on, 717
infant, vs. maternal HIV viral load, 1382
Rocky Mountain spotted fever, serologically unconfirmed, 1469
Mosquitoes, in disease transmission (*See also* Malaria)
West Nile virus meningoencephalitis, 230
Mucormycosis, Ebola virus infection with, S15
Mucosa
dendritic cells of, in HIV replication promotion, S427
HIV interactions with, S436
HIV transmission through
in breast-feeding, S405
humoral defenses against, S475
in Kenya, S401
oral
antiviral factors as barriers to, S431
primate model, S408
primate model, S413
rectal
chimpanzee model, S418
M cells and, S441
transcytosis in, S448
Mycobacterium avium complex infections, in HIV infection, S461
simian immunodeficiency virus transmission through, S480
Mucosal immunity
of genital tract, S470
HIV infection and, S392, S397, S475
to rotavirus, mouse model, S466
to simian immunodeficiency virus, S480, S489
Mucosal vaccination
cholera, S493
simian immunodeficiency virus, S489
Muscle biopsy, endothelial cell activation in cerebral malaria, 475
Mutations
CCR5 (chemokine receptor 5), HIV infection progression and, 825
CYP2C19, in proguanil resistance, 974
dihydrofolate reductase, in proguanil resistance, 974
Ebola virus, S127
enterococci, drug resistance in, 163
Epstein-Barr virus latent membrane protein 1, 240
hepatitis B virus, in carriers, liver damage and, 775
human immunodeficiency virus
disease progression and, 68
drug resistance in, 92, 249
zidovudine resistance, 705
Neisseria gonorrhoeae, S375
porin genes, 371
pneumococci, 414
Myalgia, in Ebola virus infections, S1, S28
Mycobacterium avium complex infections, in HIV infection, pathophysiology, S461
Mycobacterium leprae
infections, susceptibility to, vitamin D receptor genotype and, 187
recombinant proteins, immune response to, 1034
Mycobacterium tuberculosis (*See also* Tuberculosis)
ESAT-6 antigen, T cell response to, 637
replication in macrophages, 1213
resistance in, molecular analysis, 1025
Myeloid cells, colony-stimulating factor effects on, S342
Myeloperoxidase, impaired, in HIV infection, in pediatric patients, 584

Myositis, group A streptococci, S366

NAPDG oxidase, activation, S309
Nasal secretions, collection method for, in elderly persons, 1268
Nasal vaccination
  genital tract immunoglobulins from, S470
  simian immunodeficiency virus, S489
Nasopharyngeal carcinoma, Epstein-Barr virus antibodies in, 1108
National Institute of Allergy and Infectious Diseases, Division of AIDS Programs, S392
National Institute of Dental Research, Mucosal Infectious Disease Program, S392
National Institute of Diabetes and Digestive and Kidney Diseases, AIDS Program, S392
National Institutes of Health, HIV research programs, S392
Natural resistance associated macrophage protein 1 gene, leprosy susceptibility and, 187
Nausea and vomiting, in Ebola virus infections, S1, S8
Necrosis, lymphocytes, in human immunodeficiency virus infection, 352
Necrotizing fasciitis, group A streptococci, S366
Neisseria gonorrhoeae
  complement processing, 124
  immunoglobulin binding, 124
  infections
    human experimentation with, S375
    recurrent, molecular typing, 371
  resistance in, ciprofloxacin, 729
Neisseria meningitidis
  infections, epidemiology, disco attendance and, 751
  neutrophil response to, 1288
  vaccination
    in asplenia, 513
    serogroup C capsular polysaccharide, in elderly persons, 1433
Nelfinavir, for HIV infection
  in four-drug combination salvage therapy, 1375
  resistance to, 1356
Neonatal infections
  colony-stimulating factors for, S342
  human herpesvirus 6, 1046
  human immunodeficiency virus (*See also* Human immunodeficiency virus infection (type 1 and unspecified), transmission, perinatal)
    oral transmission, primate model, S408
  streptococci group B, maternal colonization and, 1410
Neopterin, in HIV infection, as marker, 843
Neuritis, in herpes zoster, risk categories, 9
Neurologic disorders, in Ebola virus infections, S8
Neurotoxin, eosinophil-derived, ivermectin adverse reaction, 738
Neutralizing antibodies
  in HIV infection progression, 1365
  parvovirus B19, measurement of, 619
Neutrophil(s)
  in *Candida albicans* infections
    granulocyte colony-stimulating factor effects in, 1301
    phagocytosis and killing, facilitation, 661
  chemotaxis, to *Chlamydia trachomatis*-infected cells, 954
  colony-stimulating factor effects on, S342
  impairment by endotoxin, in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
  leukocyte oxidase deficiency in, gene therapy for, mouse model, S318
  lipopolysacharide-bound, in Kawasaki disease, 508
  Neisseria meningitidis response, 1288
  respiratory burst oxidase, activation, S309
  Vibrio vulnificus phagocytosis, in chronic liver disease, 275

Nevirapine, for HIV infection
  in four-drug combination salvage therapy, 1375
  indinavir and new nucleoside reverse transcriptase inhibitors with, 1356
  indinavir with, 1116
Nitric oxide, induction of, by immunomodulators, for leishmaniasis, mouse model, 1485
Nitric oxide synthase
  inducible, deficiency, Lyme arthritis development in, mouse model, 1572
  induction of, pathways for, in lipopolysaccharide-interferon-τ stimulation, 939
  in pyelonephritis, rat model, 1162
Norwalk-like viruses, common strain with global distribution, 1334
Nosocomial infections
  Burkholderia cepacia, 1197
  Ebola virus, S8, S259
  enterococci, vancomycin-resistant, transmission, 883
  Staphylococcus aureus, methicillin-resistant, transmission, 883
NRAMP1 gene, leprosy susceptibility and, 187
Nuclear factor-kappaB
  in cytomegalovirus infection pathogenesis, 1094
  induction by vaginal lactobacilli, in HIV defense, 653
Nucleotides, synthesis of, defects, in HIV infection, 352

Obtundation, in Ebola virus infections, S1
Onchocerciasis
  epidemiology, blinding and nonblinding, Nigeria, 1576
  treatment with ivermectin, adverse reactions to, 738
Ophthalmic infections (*See* Eye infections)
Opsonin receptor response capacity, phagocytes, in cystic fibrosis, 151
Oral vaccination, simian immunodeficiency virus, S489
Original antigenic sin response, *Chlamydia trachomatis* major outer membrane protein, mouse model, 180
Osteomyelitis, *Staphylococcus aureus*, virulence factors, 291
Otitis media, pneumococcal
  rat model, 1145
  vaccination for, 1152
Outbreaks
  adenovirus infections, in military population, 1530
  Ebola virus infections (*See under* Ebola virus infections)
  hemolytic uremic syndrome, sorbitol-fermenting *Escherichia coli* strain in, 1274
  hepatitis A, from well water, 37
  rotavirus infections, 1139
  typhoid fever, multidrug-resistant, 1416
Ovary, Ebola virus infection, guinea pig model, S203
Oxidative capacity, phagocyte, in HIV infection, in pediatric patients, 584
Oxygen free radicals
  in malaria pathogenesis, 217
  in *Plasmodium falciparum* clearance, 1583

p38, in nitric oxide synthase and tumor necrosis factor induction, with lipopolysaccharide-interferon-ô stimulation, 939
Pain
  abdominal, in Ebola virus infections, S1, S8
  ocular, in Ebola virus infections, S13
  persistent, in herpes zoster, risk categories, 9
Papillomatosis, laryngeal, human leukocyte antigens and, 682
Parainfluenza virus, vaccination, monkey model, 1345
Parvovirus B19, immune response to, quantitative analysis, 619
Pediatric patients
  dengue hemorrhagic fever in, 755

diarrhea in, severe, factors associated with, 1139
Epstein-Barr virus infections in
chronic active, viral loads in, 1012
HIV status and, 1395
Escherichia coli infections in, enterotoxigenic, epidemiology, Egypt, 382
Helicobacter pylori transmission from parents, 398
hepatitis G virus (GB virus C) infections in, TT virus and, 1070
human immunodeficiency virus infection in (*See also* Human immunodeficiency virus infection, transmission, perinatal)
from breast milk, S405
Epstein-Barr virus infections in, 1395
oral transmission, primate model, S408
phagocyte oxidative capacity impairment in, 584
prevention, 319, 567
risk factors for, 52, 319
treatment, 576
malaria in
cytokine-producing T cells in, 209
reinfection resistance in, 980, 989
otitis media in, pneumococcal vaccination in, 1152
Plasmodium falciparum malaria in, reactive oxygen intermediates in, 1583
schistosomiasis with geohelminth infections in, treatment with albendazole-praziquantel combination, 996
TT virus infections in, in endemic area, 1070
viral infections in, asthma in, inflammatory mediator release in, 677
Penicillin(s)
resistance to, pneumococci, 892, S353
for streptococcal infections, group A, S366
Penicillin-binding protein, in drug resistance, S353
Peptic ulcer disease, epidemiology, vs. *Helicobacter pylori* decline, 1522
Peptidoglycan, in proinflammatory cytokine induction, 1459
Perinatal transmission, HIV (*See* Human immunodeficiency virus infection (type 1 and unspecified), transmission, perinatal)
Peripartum infections, streptococci group B, 1410
Peripheral blood mononuclear cells, HIV RNA measurement in, for antiretroviral therapy monitoring, 361
Pertussis, genotypic diversity trends, vaccination impact on, The Netherlands, 915
Phagocytes
impaired oxidative capacity of, in HIV infection, in pediatric patients, 584
opsonin receptor response capacity, in cystic fibrosis, 151
Phagocytosis
Candida albicans, enhanced with bispecific antibodies, 661
group A streptococci, rapid chemiluminescence assay for, 1293
inhibition by endotoxin, in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
Neisseria meningitidis, 1288
pneumococci, $Fc_{\delta}RIIa$ (CD32) in, 423
respiratory burst oxidase activation in, S309
Shiga toxin-producing *Escherichia coli* effects on, 503
Vibrio vulnificus, in chronic liver disease, 275
Pharmacy records, in postdischarge surgical infection identification, 434
Pharynx, group A streptococci tropism for, genetic studies, 627
Phosphorylation, in respiratory burst oxidase activation, S309
Photophobia, in Ebola virus infections, S13
Phox proteins, as respiratory burst oxidase membrane components, S309
Placenta
HIV variant selection in, 44
malaria of, immunity to, 1218
Plasma leakage, in dengue hemorrhagic fever, 755
Plasminogen, *Streptococcus pyogenes* interactions with, mouse model, 907
Plasmodium berghei, malaria, pathogenesis, mouse model, 217
Plasmodium falciparum, malaria
anemia in
interleukin-10/tumor necrosis factor-α ratio in, 279
tumor necrosis factor promoter alleles in, 287
complexity, immunity and, 989
cytokine-producing T cells in, versus age, 209
with hemoglobin E trait, 283
human leukocyte antigen alleles in, 1042
interleukin-6 in, 747
in pregnancy, fetal effects, 1579
proguanil for, 974
reactive oxygen intermediates in, 1583
resistance to reinfection, interferon-ô and, 980
severity, muscle biopsy and, 475
treatment, 1586
Plasmodium vivax, malaria, proguanil for, 974
Platelet(s), inhibition of, in hookworm infestation, 1235
Pleconaril, resistance to, coxsackievirus B3 variant, 1537
Pneumococci (*Streptococcus pneumoniae*)
antibodies to, assessment with $Fc_{\delta}RIIa$, 423
genetic variation in, 892
infections, historical review, S338
meningitis
hearing loss in, rabbit model, 264
treatment with rifampin, mouse model, 1556
otitis media
rat model, 1145
vaccination for, 1152
resistance in, S338, S353
penicillin, 892
serotype 12F, molecular characterization, 414
vaccination
in asplenia, 513
in otitis media, 1152
self heat-shock protein 60 in, 403
vaccines, S338
Pneumocystis carinii
pneumonia, mouse model, 455
variant major surface glycoprotein gene families, characterization, rat model, 192
Pneumonia
in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
colony-stimulating factors for, S342
Pneumocystis carinii, mouse model, 455
Pseudomonas aeruginosa, aerosolized dextran for, mouse model, 1449
respiratory syncytial virus, in elderly persons, disease burden, 25
Polymerase chain reaction
for *Cyclospora*-like organisms, baboon model, 670
for cytomegalovirus, in retinitis, 1249
for Ebola virus, S28
for Epstein-Barr virus, 763, 1012
for hepatitis A virus, 37
for hepatitis B virus, 775
for hepatitis C virus, in multiple transfusions, 1062
for human herpesvirus 6, 311
for human herpesvirus 8, 1533
for human immunodeficiency virus, in placenta, 44
for human T cell leukemia virus type I, 497
for *Mycobacterium tuberculosis* drug resistance, 1025
for *Onchocerca volvulus*, 1576
reverse transcriptase
for Ebola virus characterization, S164, S170

for parvovirus B19 immune response, 619
reverse transcription-competitive, for human immunodeficiency virus, 361
for *Rickettsia rickettsii*, 1469
for *Salmonella typhimurium* resistance studies, 1173
for TT virus, 686, 1242
Polysaccharide vaccines
in asplenia, 513
pneumococcal, in otitis media, 1152
por gene, *Neisseria gonorrhoeae*, mutations, 371
Porin, *Neisseria gonorrhoeae*, mutations, 371
Praziquantel
with albendazole, for schistosomiasis with geohelminthic infections, 996
for *Schistosoma haematobium*, 1515
Prednisone, for herpes zoster, pain persistence and, 9
Pregnancy
Ebola virus infections in, S11
group B streptococci serotypes in, in Japan, 1030
human herpesvirus 6 infections in, 1046
human immunodeficiency virus infection in
transmission (*See* Human immunodeficiency virus infection, transmission, perinatal)
zidovudine resistance in, 705
malaria in
fetal effects, 1579
immunity to, 1218
streptococci group B colonization in, peripartum infections and, 1410
Premature delivery, in maternal malaria, 1579
Primates, Ebola virus infections in (*See* Ebola virus infections, in primates)
Proguanil, for malaria, 974
with atovaquone, 1586
Prophylaxis, *Salmonella* bacteremia, in HIV infection, 1552
Propionate, for shigellosis, rabbit model, 390
Prostaglandins, in rotavirus inhibition, 522
Proteases, in Kawasaki disease pathogenesis, 508
Protein kinases, in HIV transcription, S44
Pseudomonas aeruginosa, infections
in cystic fibrosis
opsonin receptor response in, 151
prevention with tobramycin, 1190
pulmonary, aerosolized dextran for, mouse model, 1449
Pus Club (Interplanetary Society) Meeting (1997), March Supplement
Pyelonephritis
inflammatory mediators in, rat model, 1162
interleukin-6 response in, 172
Pyrimethamine, for malaria, 1586
Pyrogenicity, cytokines, S294

Quarantine, laboratory primates, Ebola virus infection in, S108, S281

Rac proteins, as respiratory burst oxidase membrane components, S309
Radioimmunoprecipitation, in *Trypanosoma cruzi* antibody detection, 1226
Radiometric killing assay, for antifungal activity, 661
RANTES
in HIV vaccination, 558
in respiratory secretions, in virus-induced asthma, in pediatric patients, 677
in simian immunodeficiency virus inhibition, S489
Reactive oxygen species (*See* Oxygen free radicals)
Recombinant technology, for influenza virus vaccine, ferret and chicken models, 1132
Rectum
HIV infection, treatment, S454
HIV transmission in
chimpanzee model, S418
M cells and, S441
vaccination in
cholera, S493
simian immunodeficiency virus, S489
Reflux, gastroesophageal, epidemiology, vs. *Helicobacter pylori* decline, 1522
Respiratory burst, impaired, in HIV infection, in pediatric patients, 584
Respiratory burst oxidase, activation, S309
Respiratory infections (*See also* Pneumonia)
adenovirus, in military population, 1530
Burkholderia cepacia, 1197
in cystic fibrosis, prevention with tobramycin, 1190
hantavirus, cytokines in, 295
viral, asthma in, inflammatory mediator release in, in pediatric patients, 677
Respiratory syncytial virus
immunoglobulin A specific to, nasal secretion collection method for, 1268
pneumonia, in elderly persons, disease burden, 25
vaccination, mouse model, 1326
Restriction fragment length polymorphisms, *Escherichia coli*, non-O157:H7 pathogenic Shiga toxin--producing, 115
Retinitis, cytomegalovirus
aqueous humor and vitreous viral DNA in, 1249
in HIV infection
ganciclovir resistance in, 1352
treatment, immune recovery vitritis after, 697
Retrovirus vectors, in gene therapy, for chronic granulomatous disease, S318
Reverse transcriptase, mutations, during HIV treatment, 92
Ribavirin, for Ebola virus infections, mouse model, S240
Rickettsia rickettsii, immunohistochemical detection, 1469
Rifampicin, resistance to, *Mycobacterium tuberculosis*, 1025
Rifampin, for meningitis, *Streptococcus pneumoniae*, mouse model, 1556
Ritonavir, for HIV infection
in combination therapy, viral dynamics in, 799
in early stages, 527
failure, 1375
in HAART regime, failure, 790
River blindness (onchocerciasis)
epidemiology, Nigeria, 1576
treatment with ivermectin, adverse reactions to, 738
RNA
GB virus C (hepatitis G virus), in hepatitis C coinfection, 1055
hepatitis C virus, in multitransfused hemophiliacs, 1062
human immunodeficiency virus (*See* Human immunodeficiency virus, RNA)
Rocky Mountain spotted fever, mortality in, serologically unconfirmed, 1469
Rotavirus
infections, in pediatric patients, 1139
mucosal immunity to, mouse model, S466
replication, inhibition with prostaglandin and tunicamycin, 522

S-28463 (imidazoloquinolone), for leishmaniasis, mouse model, 1485
Saliva, antiviral factors in, HIV transmission and, S431
Salivary glands, human T cell leukemia virus type I in, 497
Salmonella
bacteremia, in HIV infection, protection with zidovudine, 1552

infections, pathogenesis, S331
Salmonella abortus equi, endotoxin, leptin plasma levels and, 1047
Salmonella typhi, resistance in, multiple, 1416
Salmonella typhimurium, resistance in, 1173
Salmonellae, virulence factors, S326
SAP2 gene, as *Candida albicans* virulence factor, rat model, 201
Saquinavir, for HIV infection
in four-drug combination salvage therapy, 1375
in HAART regime, failure, 790
resistance to, 249, 1259, 1356
Schistosoma haematobium, treatment, community-wide, resolution and resurgence, 1515
Schistosomiasis
geohelminth infections with, treatment with albendazole-praziquantel combination, 996
mansoni type, acute vs. chronic, cytokine production in, 1502
Secretory aspartyl proteinase gene family, as *Candida albicans* virulence factors, rat model, 201
Selectins
in muscle, in cerebral malaria, 475
in neutrophil response to *Neisseria meningitidis*, 1288
Self heat-shock protein 60, peptide from, in pneumococcal vaccine, 403
Semen
Ebola virus in, S28, S170
human herpesvirus 8 in, 1533
Sepsis
interleukin-12 production in, chimpanzee model, 646
macrophage inflammatory proteins in, 136
pathogenesis, lipopolysacharide-bound neutrophils in, 508
Septic arthritis, *Staphylococcus aureus*, virulence factors, 291
Sexual behavior
herpes simplex virus type 2 antibody as marker for, 16
HIV infection resistance and, 59
human herpesvirus 8 seroprevalence and, 237
Neisseria gonorrhoeae resistance and, 729
TT virus prevalence and, 686
SfbI fibronectin-binding protein, in group A streptococci internalization in epithelial cells, 1049
Shiga toxin, pathogenetic effects, 503
Shigellosis
pathogenesis, S331
treatment, short-chain fatty acids, rabbit model, 390
vaccination, in pediatric patients, 1564
Shingles (herpes zoster), persistent pain in, risk categories, 9
Shock
in Ebola virus infections, S1
in streptococcal infections, S366
Short-chain fatty acids, for shigellosis, rabbit model, 390
Sialylation, *Neisseria gonorrhoeae* inflammation and, 124
Simian immunodeficiency virus, replication, in dendritic cells, S427
Simian immunodeficiency virus infection
mucosal immunity to, S480
simian T cell leukemia virus type I coinfection with, macaque model, 600
transmission
oral, S408
vaginal, S413
vaccination, S480, S489
Sjögren's syndrome, human T cell leukemia virus type I in, 497
Skin, Ebola virus detection in, S36, S274
Skin lesions
in Ebola virus infections, S1
group A streptococci, mouse model, 907
molluscum contagiosum, epidemiology, Australia, 701
Skin tests, tuberculosis, vs. whole blood interferon-ô release assay, 1293
Soluble adult worm antigen or soluble egg antigen, *Schistosoma mansoni*, cytokine response to, in acute vs. chronic infection, 1502
Sore throat, in Ebola virus infections, S1
spe genes, group A streptococci exotoxin, tissue tropism and, 627
Spleen
absence, polysaccharide vaccine response in, 513
Ebola virus infection, guinea pig model, S203
pathology, Ebola virus infections, S54
peptidoglycan isolated from, in proinflammatory cytokine induction, 1459
Splenocytes, response to *Schistosoma mansoni* antigens, in acute vs. chronic infection, 1502
Staphylococci, resistance in, S353
Staphylococcus aureus
bacteremia, recurrent, pulsed-field gel electrophoresis in, 1157
endocarditis, management, current status of, S360
infections, in cystic fibrosis, opsonin receptor response in, 151
resistance to, methicillin, 1591
transmission dynamics, 883
virulence factors, 291
Staphylococcus carnosus, biofilm formation, hemagglutination and, 1560
Staphylococcus epidermidis, biofilm formation, hemagglutination and, 1560
Stomach, *Helicobacter pylori* in, changing epidemiology, 1522
Streptococci
endocarditis, S360
group A (*Streptococcus pyogenes*)
genetic studies, 627
highly invasive, S366
internalization in epithelial cells, fibronectin-binding protein, 1049
opsonophagocytosis, rapid chemiluminescence assay for, 1293
skin infections, mouse model, 907
toxic shock syndrome, S366
vaccination, mouse model, 901
virulence factors, S366
group B
in peripartum infections, 1410
serotypes, in pregnant Japanese women, 1030
vaccination, with tetanus toxoid, 142
Streptococcus pneumoniae (*See* Pneumococci)
Streptococcus pyogenes (*See* Streptococci, group A)
Streptomycin, resistance to, *Mycobacterium tuberculosis*, 1025
Sulfadoxine, for malaria, 1586
Superoxide, induction by Shiga toxin-producing *Escherichia coli*, 503
Surgical infections
colony-stimulating factors for, S342
postdischarge, identification and data management, 434
Surveillance, for Norwalk-like viruses, common strain with global distribution, 1334
Susceptibility
to HIV (*See* Human immunodeficiency virus infection, susceptibility to)
to *Leishmania*, mouse model, S305
to leprosy, vitamin D receptor genotype and, 187
Syncytium-inducing phenotype, human immunodeficiency virus infection, prognosis with, 254
Syphilis, vertical transmission, guinea pig model, 1206

T cells
$\tau\delta$ expansion after cytomegalovirus infection, in kidney transplantation, 1
activation
in HIV infection progression prediction, 859
vaginal lactobacilli in, in HIV defense, 653
autologous, from lymph nodes, for human immunodeficiency virus infection, 245
CD4+, maternal levels, perinatal transmission and, 1388

CD8+
anti-HIV inhibitory factor, S485
maternal levels, perinatal transmission and, 1388
cytokine-producing
intracellular antigen-specific, 1124
in *Plasmodium falciparum* malaria, versus age, 209
cytotoxic, HIV-specific, in exposed seronegative persons, 538, 548
dysfunction, in tuberculosis, 945
in hantavirus pulmonary syndrome, 295
in human immunodeficiency virus infection
activation-associated necrosis, 352
viral replication in, S427
in *Pneumocystis carinii* pneumonia, mouse model, 455
proliferation, in human immunodeficiency virus vaccination, 558
response
to antiretroviral therapy, for HIV infection, 345
to GP160 HIV vaccine, 337
in human immunodeficiency virus infection, interleukin-12 enhancement, 493
to *Mycobacterium tuberculosis* ESAT-6 antigen, 637
to pneumococci, 403
to rotavirus, mouse model, S466
to simian immunodeficiency virus, S480
subsets, in leishmaniasis, mouse model, S305
suppression, by *Entamoeba histolytica*, gerbil model, 1495
Tachypnea, in Ebola virus infections, S1
TA-GW vaccine, human papillomavirus, 612
Tetanus toxoid vaccine, with group B streptococci vaccine, 142
Thermoregulation, cytokines and, S294
TI-2 antigen, immunization with, in elderly persons, 1433
Tissue tropism, of group A streptococci, genetic markers for, 627
Tobramycin, for cystic fibrosis, respiratory microbial flora population and, 1190
Toxic shock syndrome, streptococcal, S366
Toxins
Clostridium difficile, S331
Escherichia coli, S331
Toxoplasma gondii
dendritic cell response to, 467
encephalitis, in HIV infection, leukotriene inhibition in, 714
Transfusions
from convalescent patients, for Ebola virus infections, S18
from hepatitis C and hepatitis G coinfection, 1055
hepatitis C virus in, genotypic changes in, in hemophiliacs, 1062
human herpesvirus 8 antibodies in, 1590
TT virus and, 686, 1242
Transplantation
bone marrow
cytomegalovirus infections in, cytokines in, 484
human herpesvirus 6 infections in, 311
kidney, cytomegalovirus infections in
$\tau\delta$ T lymphocyte expansion after, 1
granzyme B expression in, 693
liver, fulminant hepatitis C after, 1007
Treponema pallidum, vertical transmission, guinea pig model, 1206
Trichuriasis, with schistosomiasis, treatment with albendazole-praziquantel combination, 996
Tripeptide assay, for *Trypanosoma cruzi* antibodies, 1226
Trophoblast, HIV variant selection in, 44
Trypanosoma cruzi, antibodies to, detection of, 1226
TT virus
in bile, 1245
epidemiology
in blood donors, 1242
Great Britain, 686
in pediatric patients, in endemic area, 1070
Tuberculin skin tests, vs. whole blood interferon-ô release assay, 1293
Tuberculosis (*See also Mycobacterium tuberculosis*)
detection, skin test vs. whole blood interferon-ô assay, 1293
hepatitis B with, vitamin D receptor gene variations and, 721
in HIV infection
detection, 1293
drug resistant, 1025
human leukocyte antigens in, 1051
spread, macrophage replication and, 1213
T cell apoptosis and hyporesponsiveness in, 945
Tumor necrosis factor(s)
induction of
by interleukin-12, chimpanzee model, 646
pathways for, in lipopolysaccharide-interferon-ô stimulation, 939
measurement, S294
promoter alleles, malaria pathogenesis and, 287
pyrogenicity, S294
receptors for, in dengue hemorrhagic fever, 755
Tumor necrosis factor=a
activation, in HIV infection treatment, 74
in cytomegalovirus infections, in bone marrow transplantation, 484
in Ebola virus infections, S188
in hantavirus pulmonary syndrome, 295
in HIV infection
as marker, 843
maternal levels, perinatal transmission and, 1388
pathogenesis, 832
receptor for, as marker, 843
in rectal mucosa, S454
induction of
by peptidoglycan, 1459
vaginal lactobacilli, in HIV defense, 653
inhibition by endotoxin, in acute alcohol intoxication, granulocyte colony-stimulating factor effects on, rat model, 1441
interleukin-10 ratio with, in malaria, anemia and, 279
in malaria resistance, placental, 1218
in *Pneumocystis carinii* pneumonia, mouse model, 455
Tumor necrosis factor=a, in hantavirus pulmonary syndrome, 295
Tunicamycin, in rotavirus inhibition, 522
Typhoid fever
multidrug-resistant, in Tajikistan, 1416
vaccination, with cholera and yellow fever vaccination, 522

Ulcer(s)
duodenal, epidemiology, vs. *Helicobacter pylori* decline, 1522
genital, *Haemophilus ducreyi*, 1423
Ultrasonography, in *Schistosoma haematobium* treatment evaluation, 1515
Ultraviolet radiation, in herpes simplex virus infection induction, 303
Urate production, in cerebral malaria, mouse model, 217
Uremia, transplantation, cytomegalovirus infection in, $\tau\delta$ T lymphocyte expansion after, 1
Urinary tract infections
interleukin-6 response in, 172
Schistosoma haematobium, treatment evaluation, 1515
Uveitis, in Ebola virus infections, S13

Vaccination
adenovirus, 1530
Bordetella pertussis, genotypic diversity trends, The Netherlands, 915
Candida albicans, mouse model, 1477
cholera
mucosal, S493

plus enterotoxigenic *Escherichia coli*, 107
with yellow fever and typhoid vaccination, 522
Coccidioides immitis, proline-rich antigen for, 518
Escherichia coli, enterotoxigenic, plus cholera toxin B subunit, 107
Haemophilus influenzae
in asplenia, 513
conjugate, impact in Scandinavia, 223
disease re-emergence and, 101
hepatitis B virus
in high-risk infants, 1319
non "a" determinant, in immunized infants, 259
protective antibody level, 489
seroepidemiology after, Taiwan, 367
human immunodeficiency virus
with gp120, 558, 817
with gp160, 337, 817
intracellular antigen-specific cytokine development in, 1124
mucosal, S392
human papillomavirus, 612
influenza virus
A/Hong Kong, ferret and chicken models, 1132
annually repeated, humoral immune response, 31
intracellular antigen-specific cytokine development in, 1124
intranasal, *Streptococcus pyogenes*, mouse model, 901
meningococcal, in asplenia, 513
meningococcal serogroup C conjugate, 1564
mucosal
cholera, S493
simian immunodeficiency virus, S480
nasal
genital tract immunoglobulins from, S470
simian immunodeficiency virus, S489
Neisseria gonorrhoeae, S375
Neisseria meningitidis
in asplenia, 513
serogroup C capsular polysaccharide, in elderly persons, 1433
oral, simian immunodeficiency virus, S489
parainfluenza virus, monkey model, 1345
pneumococcal, S338
in asplenia, 513
in otitis media, 1152
self heat-shock protein 60 in, 403
polysaccharide, in asplenia, 513
rectal, simian immunodeficiency virus, S489
respiratory syncytial virus, mouse model, 1326
Shigella, in pediatric patients, 1564
simian immunodeficiency virus, S480
routes, S489
streptococci, group B, with tetanus toxoid vaccine, 142
Streptococcus pyogenes, mouse model, 901
typhoid fever, with cholera and yellow fever vaccination, 522
vaccinia virus Ankara, expressing parainfluenza virus type 3 antigens, monkey model, 1345
vaginal, simian immunodeficiency virus, S489
yellow fever, with cholera and typhoid vaccination, 522
Vaccinia virus, Ankara, expressing parainfluenza virus type 3 antigens, vaccination, monkey model, 1345
Vagina
candidiasis, vaccine for, mouse model, 1477
HIV RNA in, vs. blood levels, 871
HIV transmission in, primate model, S413
lactobacilli in, as HIV defense, 653
secretions from, human herpesvirus 8 in, 1533
streptococci group B colonization, peripartum infections and, 1410
vaccination, simian immunodeficiency virus, S489
Vaginitis, *Candida albicans*, virulence factors, rat model, 201
Vaginosis, bacterial, HIV transmission in, 924
Vancomycin
resistance to, enterococci
molecular epidemiology, 163
transmission dynamics, 883
Staphylococcus aureus bacteremia related to, 1157
Varicella-zoster virus, infections, persistent pain in, risk categories, 9
Vascular cell adhesion molecule-1, in muscle, in cerebral malaria, 475
Vibrio vulnificus, survival in chronic liver disease, 275
Viral infections, asthma in, inflammatory mediator release in, in pediatric patients, 677
Virulence factors
Candida albicans vaginitis, rat model, 201
Entamoeba histolytica, 460
enteric pathogens, S331
Escherichia coli
enteropathogenic, 269
non-O157:H7 pathogenic shiga toxin--producing, 115
intracellular bacteria, S326
Mycobacterium avium complex, in HIV infection, S461
Neisseria gonorrhoeae, S375
Staphylococcus aureus, 291
streptococci, group A, S366, 627
Streptococcus pyogenes, mouse model, 907
Visceral leishmaniasis, soluble interleukin-4 receptor in, 743
Visual loss, in Ebola virus infections, S13
Vitamin D receptor
genotype, leprosy susceptibility and, 187
variants, tuberculosis-hepatitis B coinfections and, 721
Vitreous, cytomegalovirus DNA in, 1249
Vitritis, immune recovery, in cytomegalovirus retinitis, in HIV infection, 697
Vomiting, in Ebola virus infections, S1, S8

Warts, genital, treatment, vaccine in, 612
Waterborne diseases
hepatitis A, 37
rotavirus infections, 1139
typhoid fever, multidrug-resistant, 1416
West Nile virus, meningoencephalitis, risk factors for, in Romania, 230
Western blot test, for Lyme disease, 931, 1021
Wound infections, colony-stimulating factors for, S342

Yellow fever
Ebola virus infections with, S65
vaccination, with cholera and typhoid vaccination, 522

Zalcitabine, for HIV infection, resistance to, 249, 1259
Zidovudine, for HIV infection
in combination therapy, 808
viral dynamics in, 799
in early stages, 527
failure, in pediatric patients, 52
HBY 097 with, 709
in pediatric patients, 576
primary, 1548
prophylactic, 319, 567
protection against *Salmonella* bacteremia recurrence, 1552
resistance to, 92, 249, 1259
in pregnancy, 705
T cell response in, 345
in triple therapy, 329, 527
Zoster, persistent pain in, risk categories, 9